Department of Medicine 2018 ANNUAL REPORT
2018
Changing What’s Possible
Acknowledgments: The Department of Medicine would like to thank the many individuals, especially our leadership, including our Division Directors and Division Administrators, for their collective efforts in helping to complete this year’s annual progress report. Additionally, we would like to thank those who are featured within these pages for their continued service to MUSC and contributions to this publication. Editor, Creative and Production Manager: Natalie Titcomb Photographer: Elizabeth Anne Thompson
22
D E PA R T M E N T O F M E D I C I N E
Table of Contents 04 05 06 08 10 12 14
Who Are We?
16 18
MUSC Named One of the First Telehealth Centers of Excellence
20
From the Chair
Expanding Global Health Opportunities at MUSC MUSC Leads Research on Potential Lupus Treatment State-of-the-Art Health Care for Veterans Transforming Patient Care: Physician Excellence in Patient Satisfaction
22 24 26 28 30 32 34 38 40 41 42 44 48 49
Cardiology Endocrinology, Diabetes, and Metabolic Diseases Gastroenterology and Hepatology General Internal Medicine Hematology/Oncology Infectious Diseases Nephrology Pulmonary, Critical Care, Allergy, and Sleep Medicine Rheumatology and Immunology Medical Education Philanthropy Changing What's Possible Development Highlights Employee Recognition Research Funding Highlights Selected Publications Departmental Leadership Medicine Faculty
2018 ANNUAL REPORT
3
FROM THE CHAIR
From the Chair Thanks to the commitment of our faculty, staff, and leadership, the past academic year has been one of growth and progress for the Department of Medicine with many notable achievements in education, clinical care, and research. In fact, by virtually every metric, this last year has been among one of the most successful in the Department’s history. As the largest and one of the most active Departments in the MUSC College of Medicine, we are extremely proud of our outstanding physicians, researchers, and staff. In the pages that follow, I invite you to learn more about the exciting programs, research initiatives, and treatment advances taking place within the Department. Some particularly noteworthy Departmental highlights from this past year include the following: •
Our peers and our patients continue to rank Department of Medicine programs among the best in the nation. In 2018, MUSC Health was named by U.S. News & World Report as one of the country’s top 25 hospitals (#24) in the treatment of cancer and MUSC’s Nephrology program was highly ranked as well, coming in at No. 46. MUSC Health was also recognized as high-performing in four adult specialties that the Department of Medicine is critical to, including Gastroenterology & GI Surgery, Geriatrics, Pulmonology, and Rheumatology.
•
The Department’s clinical programs have continued to grow in both volume and quality over the past year. Our patient-centered medical initiatives as well as our faculty’s dedication to quality have resulted in increased patient satisfaction rates and financial success.
•
In alignment with our overarching plan to focus on wellness and burnout as a top priority in FY19, the Department of Medicine has created a well-being task force. With representation from across the Department, this committee is charged with exploring ideas for improvement, particularly in the domain of reward and recognition, and working to develop Department-based initiatives to address wellness and burnout.
•
In a highly competitive national research environment, the Department saw a 3% increase in research expenditures and an 8% increase in the number of awards from FY17 to FY18.
•
The Department’s core internal medicine residency and subspecialty fellowship programs are among the nation’s best, and we remain exceptionally proud of our outstanding trainees – many of whom become leaders at MUSC and around the world. Each year, applications to our training programs exceed the previous year, and the quality of the applicants has continued to rise along a similar trajectory.
Our Department—made up of nine divisions engaged in care at two hospital systems and multiple ambulatory practices—is guided by our vision to provide world-class patient care, to educate the next generation of physicians, and to generate groundbreaking scientific discoveries to improve human health. I extend my sincere appreciation to the dedicated faculty, fellows, residents, and staff who have contributed to our success so far, and I look forward to celebrating our future accomplishments and new initiatives in the year ahead. 4
D E PA R T M E N T O F M E D I C I N E
Don C. Rockey, M.D. Professor and Chair Department of Medicine Medical University of South Carolina
WHO ARE WE
Who are we? Faculty, Staff, & Trainees
Our achievements in education, research, and clinical care are far-reaching as we deliver the University's mission: changing what's possible.
135 Research Staff
211
Support Staff
Trainees 97 Residents 88 Fellows 26 Post Docs & Trainees
246 Faculty
23,657 Patients and Families First
92 Management &
Innovative Learning
NEW PATIENTS
Healthy Communities
$26,211,381 Total Research Expenditures in FY18
56 60 34
67 APPs
Diversity and Inclusion
Scientific Discoveries
76 NEW AWARDS PI's with Active Federal Awards
PI's with Active Corporate Clinical Research
PI's with Active Federal Clinical Research 2018 ANNUAL REPORT
5
I N N O VAT I O N
MUSC Named One of the First National Telehealth Centers of Excellence The Medical University of South Carolina (MUSC) is widely regarded as an industry leader in telehealth with a robust, high-volume telehealth program that touches not only the local community, but also impacts patients throughout the state. In October 2017, MUSC was named one of only two national Telehealth Centers of Excellence through a landmark grant awarded by the Health Resources and Services Administration (HRSA). Principal investigators Dee Ford, M.D., and Katie Cristaldi, M.D., who will serve as the Center of Excellence’s (COE) Director and Associate Director respectively, were responsible for leading the effort to pull together the federal grant application. Their painstaking efforts paid off: the grant awarded $600,000 the first year and $2 million in year two.
6
with a particular focus on rural and/or underserved areas. Through the use of high-tech videoconferencing equipment, telehealth can enable doctors many miles away to care for patients with any condition ranging from life-threatening (e.g., cardiac arrest, ischemic stroke) to basic (e.g., routine asthma care for school children). MUSC’s first telehealth program launched in 2005 with a maternal-fetal medicine program that treated women with high-risk pregnancies in underserved communities. Building on its success, MUSC opened a telestroke program in 2008. “The inception of telehealth at MUSC was grassroots-driven. Individual cli-
million in state appropriated funds to advance telehealth initiatives throughout the state. The legislature has appropriated funds each year since. “That was a huge catalyst for us,” says Ford. “Our ability to demonstrate innovation in the telehealth arena garnered support from the state.” Since the program’s humble beginnings, it has flourished in ways the teams could not have predicted. For instance, MUSC’s number of annual telehealth interactions has grown from 1,078 in 2013 to over 300,000 projected in 2018. Today, MUSC provides telehealth services to more than 200 sites in 27 counties at 28 hospitals, more than 100
The COE team will work hand in hand with the existing MUSC Center for Telehealth as it expands the scope and delivery of clinical care throughout the state. The primary COE objectives are to expand MUSC’s telehealth scope beyond a regional focus, to a national level.
“The inception of telehealth at MUSC was grassroots-driven. Individual clinicians who saw a need tried to meet those needs with telehealth technology. Early on, we didn’t have the institutional support to develop a comprehensive program.” —Dee Ford, M.D.
Furthermore, in a collaborative multidisciplinary team approach, the COE, applying rigorous scientific evaluation, will assess the effectiveness of MUSC’s telehealth services in rural and urban areas in an effort to achieve “next level” telehealth.
nicians who saw a need tried to meet those needs with telehealth technology,” says Ford. “Early on, we didn’t have the institutional support to develop a comprehensive program.”
Telehealth is an innovative, convenient, and effective way for health care providers to deliver acute, primary, and specialty medical care and support to patients located in all areas of the state,
But MUSC’s improved outcomes and demonstrated benefit to the communities MUSC serves captured the attention of the state legislature. As a result, in 2013, MUSC received $12.4
D E PA R T M E N T O F M E D I C I N E
community clinics and 50 schools, as well as alternative sites such as nursing facilities, prisons, and patients’ homes. Seventy-eight percent of sites are located in completely or partially medically underserved areas of the state. COE - The Brass Ring The Health Resources and Services Administration was looking for high-volume telehealth programs that were
I N N O VAT I O N
Dee Ford, M.D.
focused on the medically–underserved in rural areas and could demonstrate financially sustainable telehealth business models. MUSC hit the telehealth trifecta. "HRSA now wants to see how telehealth can be embedded in traditional clinical practice – not an add-on." Ford says. "They want it interwoven and integrated, and they want to see financial feasibility.” Ford explains MUSC has a lived experience of telehealth successes and failures and part of what our federal partners want to understand is how to evaluate and disseminate telehealth best practices. The MUSC Center for Telehealth will continue its clinical efforts under the leadership of James McElligott, M.D., Medical Director, and Shawn Valenta, Administrator of the Center. Moving
forward, the COE will fill important gaps in the national telehealth landscape, focusing on three priority areas: the impact of telehealth on federal and local health care spending, provider and patient engagement in telehealth, and open access network evaluation and best practice dissemination. MUSC will also develop and offer at a national level teams devoted to evaluation, dissemination, and consultation. Valenta credits the efforts of Ford and Cristaldi for leading the robust team to the win. “As co-principal investigators on the award, Dr. Ford and Dr. Cristaldi will leverage the amazing work of our Center for Telehealth’s programs and MUSC’s scientific resources to focus on recommendations and solutions to universally complex telehealth barriers.
We are extremely excited to partner with this formidable team to serve the patients throughout South Carolina and nationally to the best of our abilities.” Ford believes that critical to MUSC’s success is the people working within the telehealth programs who are fiercely committed to its mission of better meeting the health care needs of South Carolina residents. “It’s a very high-quality, high-performing, committed team. There are all different kinds of roles and ways in which people contribute to the whole program. All of this is only achievable because we have the right people to get the work done. It’s really the team that has gotten us this far,” says Ford. Original article by Mikie Hayes, MUSC Catalyst News .
2018 ANNUAL REPORT
7
I N N O VAT I O N
Expanding Global Health Opportunities at MUSC Global health refers to health issues that transcend national boundaries. As the world population becomes more mobile and diverse, maintaining a healthy domestic population becomes increasingly challenging and requires that all health care providers have greater knowledge of diseases that have typically occurred in remote geographical regions. In recent years, the Division of Infectious Diseases within the Department of Medicine has made global health a priority by implementing a number of initiatives dedicated to reducing health disparities in South Carolina and around
the world. Leading the charge is Susan Dorman, M.D., a pioneer in the field who was recruited to MUSC from Johns Hopkins University in 2017 to strengthen and expand the Infectious Diseases Global Health program.
This past year, under Dr. Dorman’s leadership, the Division of Infectious Diseases partnered with Faculty Director Michael Sweat, Ph.D., and Executive Director Kathleen Ellis of the MUSC Center for Global Health (CGH), to launch a new global health initiative. CGH is a university-wide initiative to advance MUSC’s efforts to improve health locally and around the world through research, education and training, and service. CGH does this through a number of mechanisms including a Faculty Pilot Project Grant program, a Trainee Global Health Travel Grant program, and a Certificate Program in Global Health. Through the Division’s new initiative with the CGH, Dr. Dorman is working to expand the infectious diseases research portfolio related to global health, with initial emphasis on tuberculosis as well as Divisional strengths of HIV, infection control, and antimicrobial resistance. The emergence and spread of antimicrobial resistance is considered a global threat. In May 2015, the World Health Organization endorsed a global action plan to tackle this crisis, and in the United States, its importance has been demonstrated by a presidential executive order, a national strategy, and NIH funding.
Peter Zwerner, M.D., demonstrates point-of-care ultrasound technology at a rural health clinic outside Dar es Salaam, Tanzania.
8
D E PA R T M E N T O F M E D I C I N E
Another focus of the Division’s collaborative effort with the CGH is the expansion of international research and clinical opportunities for MUSC trainees. This includes work through the Global Health Curriculum Planning Committee to develop a new medical student Global Health Flex Track. Students who choose this option will take a deep dive into global health topics
I N N O VAT I O N
Physicians at the Jakaya Kikwete Cardiac Institute conduct a cardiac procedure.
and apply their learning in research that focuses on health outcomes around the globe and in South Carolina. Students are also eligible to apply for the global health travel scholarships that the college provides for rotations in the fourth year. Now more than ever, students pursuing a career in health care are looking for rotations or experiences in developing countries that allow them to interact with other health systems. At MUSC, more than 100 students travel abroad annually – whether through participation in faculty-led research, clinical electives, or service learning. The MUSC Center for Global Health helps facilitate many of those experiences, working with students to identify sites and projects and evaluate them for their safety, academic programing, and ethical engagement in local health settings.
“In addition to enhancing clinical and scholarly work, surveys have shown that many resident physicians select their training program at least partly based on availability of global health training opportunities,” says Dr. Dorman. “And trainees who participate in international clinical rotations are more likely to later practice medicine among underserved and multicultural populations in the United States.” As the recipient of an NIH K24 mid-career investigator award, Dr. Dorman provides valuable mentorship for trainees who are interested in pursuing related global health training, especially in research fields. The dual objectives, especially with reference to fellows and junior faculty, are to foster the development of clinicians and investigators whose professional activities incorporate
the global health concepts of disparity reduction and collaborative improvement of community health. “At its core, global health requires a multidisciplinary approach,” says Dorman. Looking ahead, she plans to work with training program directors in various disciplines to establish expanded global health opportunities for residents and fellows. “It is an exciting time to be working in global health at MUSC,” says Dorman. “There are many opportunities for growth and we’re on an outstanding trajectory.”
2018 ANNUAL REPORT
9
I N N O VAT I O N
MUSC Leads Research on Potential Lupus Treatment organs, says Gilkeson. More than 16,000 new cases of lupus are reported each year, and women of color are two to three times more likely to develop it. “The severity is worse in African Americans and Hispanics, although the severity in Hispanics varies depending on their family origin, specifically Central America versus Puerto Rico versus Spain,” says Kamen. According to Gilkeson, anywhere from 40 to 60 percent of blacks and Hispanics will develop kidney damage from lupus. The rate of their progression to renal failure is five to 10 times that of whites, even when given the same treatments. “They proDiane Kamen, M.D., examines a patient. gressively have more decline over time. This progression appears to be genetically linked.” Systemic lupus causes the body’s immune cells—the defense system that usually protects against disease—to attack the The idea for using mesenchymal stem cells was planted seven body’s own tissues and organs such as the kidneys. Lupus kidyears ago when Gilkeson went to China and learned of the work ney disease is more prevalent and severe in women who are of Lingyun Sun, M.D., Ph.D., of the Affiliated Drum Tower HosAfrican American or Hispanic. pital of Nanjing University Medical School, a sister hospital of MUSC Health. “Dr. Sun presented his work, and it was very Why that is the case is just one question researchers at MUSC intriguing, so we started working with him. It’s taken almost 10 and elsewhere are pursuing, along with the goal of developing years to get to this point, but the therapy shows promise,” Gilbetter treatments to prevent the need for transplants. keson says. Researchers in the Department of Medicine’s Rheumatology In FY18, MUSC’s Division of Rheumatology was also awarded Division hope a five-year, $3.8 million grant from the Lupus Foundation of America, that was awarded in November 2017, will a comprehensive clinical center of research infrastructure grant from the National Institutes of Health for $750,000 a year for help shed light on that question. This grant provides funding for five years, one of only three such centers in the country. This a phase 2 clinical trial that will evaluate an extremely novel treatgrant supports studies to determine why African Americans have ment using mesenchymal stem cells harvested from donated more prevalent and severe lupus and scleroderma than other umbilical cords in patients with lupus resistant to treatment. ethnicities. The study, led by the Medical University of South Carolina’s MUSC’s Center for Cellular Therapy houses an FDA-registered Gary Gilkeson, M.D., and Diane Kamen, M.D., marks a milecGMC facility approved to manufacture cells for human therastone in lupus research, which has only had one drug developed peutic use. There are only 15 such centers in the country, and the specifically for lupus and approved by the U.S. Food and Drug existence of this center at MUSC was a necessity for the funding Administration. The National Institutes of Health is partnering in of this project. The center will provide the mesenchymal stem this study, granting $3.5 million additional dollars over five years cell therapy for all seven medical facilities involved with the trial. to determine how the stem cells are affecting lupus. More treatment options for lupus are needed, given the number of people affected by this chronic autoimmune disease that can damage any part of the body, including the skin, joints, and 10
D E PA R T M E N T O F M E D I C I N E
“The stem cells don’t carry immune markers on them, allowing us to give cells from an unrelated donor to lupus patients. About 15 patients can be treated with cells from one cord,” says
I N N O VAT I O N
Gilkeson. “We don’t know exactly how they work, but we know they suppress the immune system and cause profound changes on the immune parameters. They reduce the abnormal reactions of the patients’ systems attacking themselves.” The NIH grant will provide the funding to identify how the cells work. Early responses in six patients treated in the phase I trial are encouraging, with five patients who had not responded to standard lupus therapies improving in their lupus symptoms after receiving the therapy. All patients are aware they are getting the cells, and no patients experienced adverse reactions, says Gilkeson. The expansion of the phase 2 trial is now underway and will enroll 81 people with lupus who are not responding well to current treatments. The trial is expected to last through June 2022, with the five patients enrolled in the first month the trial was open. The trial will expand to seven additional academic centers in Atlanta, Chapel Hill, Chicago, Los Angeles, Rochester, and San Diego, with MUSC being the lead center. Over a hundred patients have reached out to see if they can be part of the study. Though more study is needed on why it works, it seems that the mesenchymal stem cell treatment activates T-regulatory cells, which modulate the immune system and occur in lower amounts in lupus patients. It also seems to knock out double below:
negative B cells, or B cell lymphocytes, a type of white blood cell that is increased in lupus, to get them to a normal level, says Gilkeson. “It doesn’t work for everyone, but there are encouraging results overall,” Gilkeson says, adding that other researchers are exploring this technique for wound healing, bone grafting, graft-versus-host disease, kidney transplants, and islet cell transplants. Gilkeson, who has studied lupus for more than two decades, says he’s grateful for the funding that will determine whether this novel therapy will be a game changer for lupus treatment. He sees the toll the disease can take. The Lupus Foundation of America was the first organization to see the potential for stem cell treatment in people with lupus and over the past 10 years provided funding of $1.2 million to researchers at multiple institutions to explore its utility. Though it can affect men and women at any age, it tends to occur in young women. “It’s compelling to me because it is so common in young women in their 20s who are just starting out in their careers and their families,” Gilkeson says. “It’s a serious disease that can be life threatening. We have some treatments, but we need better therapies. With this new treatment, our goal is to allow them to lead normal lives.” Original article by Dawn Brazell, MUSC Catalyst News.
(L-R): Diane Kamen, M.D., and Gary Gilkeson, M.D.
2018 ANNUAL REPORT
11
V E T E R A N ' S A F FA I R S
State-of-the-Art Health Care for Veterans in the Lowcountry and Beyond Highlights from the Medicine Service at the Ralph H. Johnson VAMC in 2018 CLINICAL CARE The Department of Medicine is a primary partner of the Ralph H. Johnson Veterans Affairs Medical Center (VAMC) which provides a full range of patient care services, as well as educational and research opportunities. As a premier teaching hospital, the VAMC is a 152-bed tertiary care facility that serves over 80,000 veterans along the South Carolina and Georgia coasts. As a level 1A facility, the Charleston VAMC is one of the fastest-growing VAMC’s in the nation. It is consistently ranked in the top 10th percentile for quality according to the Healthcare Effectiveness Data and Information Set (HEDIS) and has sustained a high level of performance on the VA's Strategic Analytics for Improvement and Learning (SAIL) rating system for the past several years. The VA Medical Center is a leader in cardiac care, cardiothoracic surgery, and mental health care, and provides a range of comprehensive specialty health care services in cardiology, dermatology, endocrinology, gastroenterology, hematology/oncology, infectious diseases, nephrology, pulmonary, rheumatology, and women’s health. The facility is the site of the VA’s first National Tele-Mental Health Hub, providing evidence-based psychotherapies for PTSD, as well as an extensive Homeless Veterans program, including services such as the Compensated Work Therapy program and the Housing and Urban Development-VA Supported Housing (HUD-VASH) program. Serving those “who shall have borne the battle” continues to be a privilege that comes with great responsibility. The Medicine Service at the Ralph H. Johnson VAMC in partnership with the Medical University of South Carolina is proud to take on this responsibility and looks forward to continuing to find new and better ways to meet the health care needs of veterans across the Lowcountry and beyond. RESEARCH Veterans receiving care at the Ralph H. Johnson VA Medical Center benefit from an extensive research program directed by R. Amanda LaRue, Ph.D., Associate Chief of Staff, Research & Development. The VAMC's robust research program has more 12
D E PA R T M E N T O F M E D I C I N E
than 90 investigators involved in 280+ projects funded at $28.8M annually. In 2018, cutting-edge research efforts in the Medicine Service focused on novel therapies in heart failure, including cell therapy, the diagnosis and treatment of fatty liver disease, and access to the National Cancer Institute (NCI) infrastructure offering cancer patients access to NCI-sponsored clinical trials. Complementing the Ralph H. Johnson VAMC world-class cardiac care is cutting edge research led by Department of Medicine investigators Michael Zile, M.D., Valerian Fernandes, M.D., and Sheldon Litwin, M.D., who have been instrumental in a Department of Defense-sponsored cell therapy study for HFpEF (Heart Failure with preserved Ejection Fraction); and the work of Terrence O’Brien, M.D., in the “PARADISE-MI” trial evaluating the benefits of sacubitril/valsartan in the treatment of heart failure patients. Extending this expertise into clinical care, the VAMC’s Cardiology Service now offers complex electrophysiologic services, including atrial and ventricular arrhythmia ablations, cardiac catheter treatments for total coronary occlusions and refractory angina, and a novel home cardiac rehabilitation program. In 2018, under the direction of Wing Syn, Ph.D., the VAMC’s Gastroenterology Service was named one of five sites to be part of the National Steering Committee for the VA Non-Alcoholic Fatty Liver Disease (NAFLD) Research Consortium. The Ralph H. Johnson VAMC offers four NAFLD clinics per week, including transient elastography in addition to the new services of capsule endoscopy, “smart pill” motility studies, inbody composition analysis and others. As one of 11 VA sites in the nation participating in the National Cancer Institutes and VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE) initiative, the Ralph H. Johnson VAMC is at the forefront of cancer care for veterans. This infrastructure allows veterans to participate in NCI trials such as precision-medicine therapies based on genetic profiles and cures using the patient’s own immune system. Tying into the patient-centered focus of the VAMC’s Hematology and Oncology Service is the 2018 expansion of the Nurse Navigator program led by Rinah
V E T E R A N ' S A F FA I R S
above: Department
and Section Leadership of the Medicine Service at the Ralph H. Johnson VAMC (L-R): Wing-Kin Syn, Ph.D., (Acting Chief, Gastroenterology), Jyotika Fernandes, M.D., (Chief, Endocrinology and Metabolism), Yuval Naot (Attending Hematology and Oncology for Rinah Shopnick, D.O., Chief, Hematology and Oncology), Michael Zile, M.D., (Chief, Cardiology), William Groh, M.D., (Associate Chief of Staff, Medicine), Ronald Washburn, M.D., (Chief, Infectious Diseases), Johann Herberth, M.D., Ph.D. (Deputy Chief, Medicine)
not pictured: Michael Ullian, M.D., (Chief, Nephrology), Athena Beldecos, M.D., (Chief, Hospitalist), Graciela De Jesus, M.D., (Chief, Dermatology), Lancer Scott, M.D., (Chief, Emergency Medicine), Michael Frye, M.D., (Acting Chief, Pulmonary and Critical Care), and Holly Mitchell, M.D. (Chief, Rheumatology)
Shopnick, D.O. Under this new program, all veteran cancer patients treated at the VAMC are now followed by a nurse navigator, resulting in improved continuity and better health outcomes. EDUCATION Medical training continues to be a fundamental activity for over 300 medical students, residents, and fellows who rotate through the Medicine Service each academic year. Dedication to training future generations of health care providers is at the core of the VAMC’s Emergency Medicine Service directed by Lancer Scott, M.D. In 2018, the service completed an expansion and renovation of the Emergency Department which now includes a state-of-the-art mental health emergency assessment and treatment area. Continued recruitment of VAMC faculty with board-certified emergency medicine physicians has expanded emergency medicine teaching rotations to physician assistant students and residents in emergency medicine and internal medicine at MUSC.
80,000 The VAMC serves over 80,000 veterans along the South Carolina and Georgia coasts.
2018 ANNUAL REPORT
13
T R A N S F O R M I N G PAT I E N T C A R E
Transforming Patient Care The Department of Medicine has a long-standing reputation for excellence in patient care. Multiple Departmental programs are currently ranked as the best programs in the state of South Carolina, and in the region. As the largest Department in the MUSC College of Medicine, the Department of Medicine is dedicated to improving patient safety, value, and satisfaction along with an emphasis on optimizing patient and employee engagement. This past year, six Department of Medicine faculty members were recognized for ranking in the 95th percentile in patient satisfaction on the CAHPS Clinician & Group Survey for all four quarters of FY18. These scores speak highly of their commitment to patient care, particularly as it relates to helping patients find the very best internal medicine options possible. Creating a patient- and family-centered environment of care is exactly what the MUSC Department of Medicine is all about. The dedication these faculty members have demonstrated to both MUSC and their patients is noteworthy and represents sustained excellence in that endeavor.
John Wrangle, M.D., with a patient
PHYSICIAN EXELLENCE IN PATIENT SATISFACTION Elisha Brownfield, M.D.
Michael Craig, M.D.
Dr. Elisha Brownfield received her medical degree from the Medical College of Virginia and completed her internal medicine residency at the Bowman-Gray School of Medicine/North Carolina Baptist Hospital. Dr. Brownfield is a member of the Society of General Internal Medicine and has served as the president of this group’s southern region. She is a fellow of the American College of Physicians and a member of the Association of Program Directors of Internal Medicine. She has been chosen as one of the Best Doctors of America on multiple occasions.
Dr. Michael Craig received his medical degree from the Medical University of South Carolina, and also completed an internal medicine residency where he served as chief resident. Following his residency, Dr. Craig completed a cardiology fellowship at MUSC and a heart failure fellowship at Ohio State University in Columbus, OH. Dr. Craig served as the Associate Director of the Cardiology Fellowship program from 2009-2013 and then as Director from 2013-2017. His clinical interests center around advanced heart failure and those in need of cardiac transplantation and ventricular assist device therapy.
Associate Professor, Director, Strategic Leadership Development (MUSC), Vice Chair for Leadership (DOM) Division of General Internal Medicine
14
D E PA R T M E N T O F M E D I C I N E
Assistant Professor Division of Cardiology
T R A N S F O R M I N G PAT I E N T C A R E
PHYSICIAN EXELLENCE IN PATIENT SATISFACTION
Val Fernandes, M.D.
Michael Ullian, M.D.
Dr. Valerian Fernandes received his MBBS from St. John’s Medical College in 1989, post-graduate M.D. from PGIMER, India in 1992, and MRCP-UK degree in 1994. He completed his medicine residency at the Mayo Clinic, followed by a cardiology and interventional cardiology fellowship at Baylor College of Medicine, Houston. Dr. Fernandes is board certified in cardiovascular disease, interventional cardiology, echocardiography, and nuclear cardiology. His clinical interests include complex coronary interventions, rotational atherectomy, alcohol septal ablation, and mitral valvuloplasty. He is actively involved in HOCM research.
Dr. Michael Ullian received his medical degree from New York University in 1981. He completed his residency at Bellevue Hospital at New York University, followed by a fellowship in nephrology at the University of Colorado. Dr. Ullian is board certified in internal medicine/nephrology. Most recently, Dr. Ullian’s research focuses on the clinical aspects of peritoneal dialysis. Dr. Ullian is a member of the American Society of Nephrology and the Southern Society for Clinical Investigation. He also serves on the editorial board for Advances in Chronic Kidney Disease and is an associate editor for the American Journal of Medical Sciences.
Timothy Whelan, M.D.
John Wrangle, M.D.
Dr. Timothy Whelan received his medical degree from State University of New York and completed his internal medicine residency at the University of Colorado Health Sciences Center in Denver. He then completed a fellowship in pulmonary and critical care medicine at the University of Washington in Seattle. Dr. Whelan is a member of the International Society for Heart and Lung Transplantation, the American College of Chest Physicians, and the American Thoracic Society. He specializes in advanced lung diseases with a clinical interest in lung transplant and interstitial lung diseases.
Dr. John Wrangle is a board-certified medical oncologist. His clinical specialties include non-small cell lung cancer and small cell lung cancer. Dr. Wrangle received his medical degree from Tulane University School of Medicine. He completed a residency in internal medicine at Emory University School of Medicine, followed by fellowship training at Johns Hopkins University. Dr. Wrangle’s research interests focus on the development of novel therapeutic strategies and biomarkers for the treatment of non-small cell lung cancer (NSCLC).
Professor, Director, Cardiac Catherization Laboratory Ralph H. Johnson VAMC Division of Cardiology
Professor Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine
Professor, Nephrology Section Chief, Veteran's Affairs Division of Nephrology
Assistant Professor Division of Hematology and Oncology
2018 ANNUAL REPORT
15
CARDIOLOGY
Under the direction of Thomas Di Salvo, M.D., the Division of Cardiology has enjoyed continued expansion across its clinical, research, and educational programs in FY18. As one of the toprated centers for cardiovascular care in the Southeast, the MUSC Health Heart & Vascular Center offers quality, comprehensive, patient-centered cardiovascular care by a team of renown physicians integrating leading-edge technology. Division faculty treat many cardiovascular conditions and diseases with leading treatments and procedures—resulting in quality outcomes tracked against national benchmarks. Additionally, as an academic medical center, faculty conduct important ongoing heart and cardiovascular clinical trials and research studies, advancing the field. Their agenda-setting initiatives have brought about several remarkable developments this year.
16 16
D E PA R T M E N T O F M E D I C I N E
C A R D I O LO G Y
Ryan Tedford, M.D., speaking with a patient.
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL This past year, under the direction of Daniel P. Judge, M.D., a world-renowned expert in cardiac genetic disease and heart failure, the Division established a new Inherited Heart Disease program. This program provides a unique focus on the diagnosis and treatment of inherited heart disease, including amyloidosis, hypertrophic cardiomyopathy, Marfan syndrome, and Loeys-Dietz syndrome. Adults and children undergo diagnostic genetic testing and consultations with a certified medical genetics counselor. Led by Ryan J. Tedford, M.D., FACC, FAHA, FHFSA, the Division launched an Invasive Cardiopulmonary Exercise Testing program (CPET) at MUSC in FY18. This program provides multidisciplinary and comprehensive invasive cardiopulmonary exercise testing to study and diagnose all forms of abnormal pulmonary vascular responses to exercise for clinical and research purposes.
Division’s basic research program received more than $1.9 million in funding and total clinical grant funding exceeded $6.3 million. EDUCATION The Cardiology Fellowship Program within the Division of Cardiology has trained over 100 cardiologists over the past 40 years, including a large percentage of the cardiologists currently practicing in South Carolina. Today, the program selects six general clinical cardiology fellows each year for the three-year program. In addition, specialty fellowship programs in Interventional Cardiology and Electrophysiology have been fielded for over thirty years. Right now, there are 24 total clinical fellows in the Division of Cardiology. The Division of Cardiology has been awarded a T32 training grant continuously for the past 35 years to support fellows in research. Currently, 11 fellows are supported by this T32 mechanism.
RESEARCH The Division’s basic and clinical research programs have continued to flourish with important accomplishments, publications, and funding of new projects. The Division maintains a robust clinical research program with more than 40 ongoing trials in cardiac arrhythmia, congestive heart failure, coronary intervention, and heart transplant. In FY18, the
Faculty and Staff Awards and Recognition: Steve Vinciguerra, MHA: Received the 2018 Administrators of Internal Medicine (AIM) Distinguished Service Award.
2018 ANNUAL REPORT
17
ENDOCRINOLOGY, DIABETES, & METABOLIC DISEASES
Under the leadership of Timothy Lyons, M.D., FRCP, the Division of Endocrinology, Diabetes, and Metabolic Diseases continues its legacy of providing compassionate, individualized patient care, advancing novel research, and educating the next generation of leaders in the field. The Division’s clinical programs provide specialized outpatient and inpatient diagnostic and treatment services to patients throughout the Charleston area and the region. Subspecialty clinics utilize a multidisciplinary approach to treat all aspects of endocrinology, including diabetes, thyroid disease, thyroid cancer, osteoporosis, and pituitary disorders. Basic and clinical research on the causes and treatments of endocrine disease are a vital part of the Division’s mission with a strong emphasis on collaboration between clinicians and basic scientists. Over the past five decades, the Division’s internationally renowned investigators have had leading roles in initiating, designing, and conducting landmark studies that revolutionized the care of patients with endocrine disorders such as diabetes. The Division has attained regional, national, and international prominence due to the efforts of its world-class team of investigative and clinical faculty who have established patient-centric programs at the forefront of research in diabetes and metabolic diseases.
18 18
D E PA R T M E N T O F M E D I C I N E
E N D O C R I N O LO G Y
Clare Kelly, Ph.D.
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL In FY18, the Division expanded its clinical services with the recruitments of two new faculty members: Aundrea Loftley, M.D., Assistant Professor, and Harsha Karanchi, M.D., Assistant Professor. Certified diabetes educators, podiatrists, nutritionists, and nurse practitioners experienced in diabetes management and endocrine testing provide integral support and expertise in the Division’s clinics. Collectively, the team had approximately 10,288 outpatient visits in FY18. The Division's Diabetes Management Service cared for over 6,400 inpatients between its Ashley River Tower, Medical University Hospital, IOP, and Children's Hospital locations in FY18. RESEARCH The Division has a longstanding tradition of excellence in research, highlighted by major discoveries in the areas of glucose management and diabetes. In FY18, the Division’s research portfolio continued to expand. New grants this year included the following: • Hesham El-Shewy, Ph.D., was the awardee of an American Heart Association grant to study sphingolipids and calcium mobilization. • Yan Huang, M.D., Ph.D., was awarded an NIH R01 to study acid spingomyelinase as a target in metabolic syndrome-exacerbated periodontitis. • Timothy Lyons, M.D., FRCP, received funding from the Yaschik Foundation to purchase a system to provide
storage and safety for unique, irreplaceable samples from some of the world’s most important studies of diabetes complications, including the DCCT/EDIC and VADT. • Louis Luttrell, M.D., Ph.D., was the recipient of an NIH R35 grant to study the pharmacodynamics of biased G protein-coupled receptor agonism. EDUCATION One of the highest priorities within the Division of Endocrinology, Diabetes, and Metabolic Diseases is to foster communication and collaboration between the Division’s clinical and basic science groups. In FY18, the Division established a weekly ‘translational meeting’ to serve as a union of these groups. This has enhanced the Division’s educational mission and provided a forum for the generation of new ideas and projects, all in an effort to improve the lives of patients. In FY18, the Division appointed Nicoleta Sora, M.D., as the new Program Director for the Endocrinology Fellowship program.
Faculty and Staff Awards and Recognition: Louis Luttrell, M.D., Ph.D.: Inducted into the prestigious Association of American Physicians.
2018 ANNUAL REPORT
19
GASTROENTEROLOGY AND HEPATOLOGY
The past academic year has continued to define the Division of Gastroenterology and Hepatology as a progressive center of excellence dedicated to advances in laboratory and clinical science, state-of-the art clinical care, and the education of future leaders in digestive and liver diseases. The Division’s nationally recognized Digestive Disease Center brings together a multidisciplinary team of gastroenterologists, surgeons, hepatologists, and radiologists to provide the highest level of comprehensive care for patients with a wide variety of digestive diseases and disorders. The Division specializes in areas such as advanced endoscopy, inflammatory bowel disease, motility disorders, and a wide variety of liver diseases, including liver transplantation, and its educational program trains 12 fellows per year in these areas. In addition to being leaders in the clinic, Division faculty are also leaders in their respective areas of research which span such varied interests as biliopancreatic disease to esophageal reflux and inflammatory bowel disease, colon cancer and polyps, liver disease and liver failure, hepatopulmonary syndrome, nutrition and obesity, liver fibrosis, and liver transplantation. In addition to establishing several new clinical offerings in just a few short years, the Division’s physician-scientists and research faculty continue to expand our understanding of the most challenging digestive diseases afflicting patients today.
20 20
D E PA R T M E N T O F M E D I C I N E
G A S T R O E N T E R O LO G Y A N D H E PATO LO G Y
B. Joseph Elmunzer, M.D.
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL In August 2018, the Division was once again recognized as high-performing by U.S. News & World Report, meaning that it is among the top 10 percent of such gastroenterology programs in the country. In FY18, the Division welcomed new faculty member Aylin Tansel, M.D., MPH, Assistant Professor, who specializes in diseases of the esophagus and foregut, including esophageal motility disorders. Over 13,860 endoscopic and motility procedures are performed at MUSC each year, and in FY18, Division members provided care to approximately 4,161 new outpatients. RESEARCH With over $25 million in annual research funding, investigations in pancreaticobiliary and esophageal disorders, gastrointestinal cancer, IBD, and liver disease serve as the cornerstone of the Division’s research programs. The Division continues to be highly successful and a national leader in developing and obtaining large, cutting-edge extramural grants. These types of awards have helped to sustain MUSC’s national and international reputation in
research areas ranging from basic science to outcomes research. Division faculty have also obtained multidisciplinary and multiinstitutional collaborative National Institutes of Health grants. Highlights of several of these grants are found below: • Gregory Cote, M.D., and Peter Cotton, M.D., received an NIH/NIDDK R01 grant to study patients who undergo ERCP for SOD, with a careful analysis of patient-reported outcomes and factors associated with improvement. The goal is to establish the precise characteristics of patients who benefit, and of those who do not, to better inform future practice. • Don Rockey, M.D., was awarded an NIH/NIDDK R01 grant to investigate “A molecular approach to the pathogenesis of portal hypertension.” In FY18, the Division launched the MUSC Digestive Disease Research Center (DDRC). The goal of the DDRC is to enhance research infrastructure and expand research capacity to enable outstanding, collaborative biomedical research in digestive and liver diseases. The Center is dedicated to fostering and facilitating the interdisciplinary and collaborative research of its 55 current members and the career development of junior faculty. Currently, twenty-seven full members contribute to a stable research base of $8.3M.
2018 ANNUAL REPORT
21
GENERAL INTERNAL MEDICINE
Growth and progress have been an ongoing theme this year for the Division of General Internal Medicine—led by William Moran, M.D.— with notable achievements in education, clinical care, and research. The Division encompasses a highly talented and committed faculty who are recognized nationally in the areas of medical education, ethics, clinical care, and research in health care disparities and outcomes. The Division continues to be recognized for its significant teaching efforts and leadership in the MUSC College of Medicine as well as its strong community partnerships and outreach programs. Most recently, successful recruitment has allowed for the continuing expansion of the Division’s efforts, promising an exciting year.
22 22
D E PA R T M E N T O F M E D I C I N E
GENERAL INTERNAL MEDICINE
General Internal Medicine Research Services Team
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL Under the direction of Kim Davis, M.D., the Division’s University Internal Medicine (UIM) primary care team provided care for 41,930 outpatients in FY18 at its Rutledge Tower and East Cooper practices. MUSC’s Palliative Care Program, directed by Patrick Coyne, MSN, received a $1.3 million grant from The Duke Endowment to create a statewide, palliative care telehealth program. The new initiative will allow palliative care providers at MUSC to deliver comfort care and end-of-life care to patients at hospitals across the state, particularly in rural areas. Under the direction of Benjamin Kalivas, M.D., and Kristine Harper, MSN, RN, NE-BC, the Division launched a novel program to begin screening non-ICU, adult patients for delirium. These efforts have resulted in a reduction in patient falls and the use of mechanical restraints. RESEARCH In FY18, GIM faculty were successfully awarded approximately $1.5 million in research funding. New grants include the following: • Andrew Schreiner, M.D., received a five-year NIDDK K23 award to develop a clinical decision tool to help primary care physicians recognize and treat chronic liver disease in its early stages.
• Samuel Schumann, M.D., was awarded a supplementary HRSA grant to improve the treatment of opioid use disorder in primary care. This collaborative effort between the Departments of Internal Medicine, Family Medicine, Pediatrics and Psychiatry is focused on improving identification, diagnosis. and treatment of opioid use disorder in primary care with an emphasis on medicationassisted therapy. Elizabeth Kirkland, M.D., was accepted into the NINDS Clinical Trials Methodology Course (CTMC), a rigorous course comprised of distance learning activities, a required residential course, and small group mentorship from experienced clinical trialists and biostatisticians. EDUCATION In July 2018, the College of Medicine, in conjunction with Elizabeth Kirkland, M.D., and Marc Heincelman, M.D., expanded the Internal Medicine Clerkship rotation from six to eight weeks with a specific focus on adding outpatient training, an essential component of medical school education. Two weeks of this required clerkship are now spent in the outpatient setting. This advance in education would not be possible without MUSC's University Internal Medicine (UIM) clinic which is providing the majority of preceptors for this critical education component. 2018 ANNUAL REPORT
23
HEMATOLOGY/ ONCOLOGY
Under the direction of Carolyn Britten, M.D., the Division of Hematology/ Oncology has continued to enjoy national and international prominence for its impactful contributions to the Department’s clinical, research, and education missions in FY18. As the largest academic cancer center in South Carolina, the MUSC Hollings Cancer Center (HCC) is the state's only National Cancer Institute (NCI)-designated cancer center and one of only 69 NCI centers in the U.S. As an integral component of the Hollings Cancer Center, the Division builds upon a long history of excellence in hematology and hematological malignancies, as well as solid tumor oncology and bone marrow transplant. Division faculty are leaders in the fields of cancer care and blood disorders. Their commitment to these fields is reflected in the many achievements and recognitions they received this year.
24 24
D E PA R T M E N T O F M E D I C I N E
H E M ATO LO G Y/ O N CO LO G Y
3-D rendering: cancer cell oncology and DNA strand
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL In August 2018, MUSC Health was recognized by U.S. News & World Report as one of the country’s top 25 (#24) hospitals in the treatment of cancer. Established more than 30 years ago, the Bone and Marrow Transplant (BMT) program at MUSC continues to be South Carolina’s leader in blood and marrow and stem cell transplantation. Under the direction of Robert K. Stuart, M.D., hematologist-oncologist at Hollings Cancer Center, the BMT program performed 115 bone marrow transplants in FY18. In May 2018, the adult BMT program opened an outpatient transplant program where patients can receive high dose chemotherapy, stem/bone marrow cells, and follow up care in the ambulatory setting. These services offer patient-centric care at a lower cost while opening hospital beds for the more acute oncology patients. RESEARCH
a recent clinical trial, led by John Wrangle, M.D., and Mark Rubinstein, Ph.D., to treat lung cancer show that a novel immunotherapy combination is highly effective at controlling the disease’s progression. The study, published April 4 in the journal The Lancet Oncology, focused on non-small cell lung cancer, which is the most common form of lung cancer. In FY18, the Paul Calebresi K12 was renewed with Michael Lilly, M.D., as the PI. The goal of the K12 Paul Calabresi Career Development for Clinical & Translational Oncology program is to train successful, patient-oriented, clinical- and laboratory-based investigators who can work effectively in a collaborative, translational research setting. EDUCATION Jenny Riley, M.D., Hematology/Oncology chief fellow (in FY18) received the South Carolina Oncology Society Outstanding Fellow of the Year award.
In a groundbreaking development this past year, results from
2018 ANNUAL REPORT
25
INFECTIOUS DISEASES
The Division of Infectious Diseases, under the leadership of Cassandra Salgado, M.D., MS, continues its commitment to patient-centered clinical programs, research, educational activities, and public health efforts. The Division’s clinical programs include all aspects of infectious diseases, from common community-acquired infections, to life-threatening diseases in those with compromised immune systems. Division faculty provide leadership for a variety of MUSC hospital and public healthoriented services, including infection control and hospital epidemiology, antimicrobial stewardship, vascular access, and transplant infectious diseases. For more than 25 years, the Division has provided comprehensive care and services to HIV-infected adults, with key funding support from the HRSA Ryan White Program and SC DHEC. The research programs in the Division continue to build on long-standing strengths in HIV/AIDS, tuberculosis, antimicrobial resistance, health care-acquired infections, musculoskeletal infections, and infectious complications from solid organ transplantation. In addition, the Division maintains its commitment to educating the next generation of physicians and scientists to meet the many challenges of an evolving landscape of infectious diseases. Most recently, the Division has been energized with recruitments designed to advance clinical programs and subspecialty training programs, clinical and laboratory research, and global health programs.
26 26
D E PA R T M E N T O F M E D I C I N E
INFECTIOUS DISEASES
(L-R): John Gnann, M.D., Deeksha Jandhyala, M.D., and Jessica Lewis, M.D.
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL With the arrival of Jessica Lewis, M.D., Assistant Professor, and Deeksha Jandhyala, M.D., Assistant Professor, in collaboration with John Gnann, M.D., Professor, the Division is poised to offer expanded, comprehensive Infectious Diseases services for solid organ and hematopoietic stem cell transplant patients. This includes expanded ambulatory services and research efforts to define the epidemiology of multidrug-resistant infections in transplant patients and develop appropriate treatment algorithms. Under the direction of Cassandra Salgado, M.D., Hospital Epidemiologist, and Scott Curry, M.D., Associate Hospital Epidemiologist, MUSC achieved its best year to date for reduction of health care-acquired infections. In FY18, there were 19 fewer device associated infections, 34 fewer surgical site infections, and 22 fewer Clostridium difficile infections. Eric Meissner, M.D., Ph.D., Assistant Professor and Director of HIV and Hepatitis Services for the Division, has partnered with the MUSC Emergency Department, the Department of Pharmacy, and SC DHEC to help improve the local treatment cascade of diagnosis, linkage, and treatment for patients with hepatitis C virus (HCV) infection. In collaboration with the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Susan Dorman, M.D., Professor, has established a clinic dedicated to the care of patients with non-tuberculous mycobacteria disease. These emerging, often difficult to diagnose and treat infections require advanced
knowledge of the epidemiology, pathogenesis, and antibiotic susceptibility patterns of the various species. RESEARCH • Scott Curry, M.D., Assistant Professor, current holder of an NIH K23 award, received CDC funding to determine the prevalence of C. difficile colonization upon admission to the hospital as well as acquisition of the organism and development of disease. • Eric Meissner, M.D., Ph.D, Assistant Professor, current holder of an NIH K08 award, was selected to be a junior investigator for MUSC’s COBRE in Digestive and Liver Disease. This program grant promises to develop junior faculty members into R01-funded independent investigators. • Julie Westerink, M.D., Professor, was the recipient of a VA Merit Award to study immune response to pneumococcal vaccination in aging renal transplant recipients. EDUCATION Susan Dorman, M.D., continues to provide key leadership for the MUSC Center for Global Health (CGH). This includes work through the Global Health Curriculum Planning Committee to develop a new medical student Global Health Flex Track as well as revision of the Tanzania medical student rotation offered annually to fourth year students. Additionally, as an NIH K24 mid-career investigator award recipient, Dr. Dorman provides valuable mentorship for trainees interested in pursuing related global health training.
2018 ANNUAL REPORT
27
NEPHROLOGY
The Division of Nephrology at MUSC has a long and notable history in the study of and potential treatments for kidney disease. Under the leadership of Joshua Lipschutz, M.D., the Division enjoyed another productive year marked with accomplishments in education, research, and patient care. With a team of nationally renowned faculty, the Division of Nephrology is consistently among the highest-ranked programs in the country. Clinical faculty provide a complete range of consultative, diagnostic, and treatment services for patients with kidney diseases. The scope of care encompasses all stages of kidney disease, from the earliest detectable changes in kidney function through end-stage renal disease. In addition, faculty members are actively involved in innovative basic science, outcomes, and clinical research aimed at better treatment options as well as prevention of kidney-related health issues. Active collaborations between clinicians and basic scientists are ongoing, and collaborations with faculty from other divisions and departments are priority. The Division hosts a flourishing fellowship program that supports 10 fellows. The publications, honors, and grant funding received by Division faculty this year highlight the quality and ingenuity of work being done in the Division to advance cures for kidney disease through scientific discoveries, cutting-edge treatments, and renal transplants.
28 28
D E PA R T M E N T O F M E D I C I N E
N E P H R O LO G Y
Milos Budisavljevic, M.D., and nephrology fellows with a patient in the Dialysis Clinic.
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL In August 2018, the MUSC Health Nephrology team was ranked 46th in the U.S. News & World Report list of best nephrology programs, placing it in the top 1% of programs nationwide. Over the past year, Division faculty cared for approximately 600 chronic dialysis patients at eight DCI outpatient hemodialysis units, the DCI home dialysis program, and the Ralph H. Johnson VA Medical Center (VAMC). Established more than 30 years ago, the kidney transplant program at MUSC has continued to expand. Under the direction of transplant surgeon Derek DuBay, M.D., and transplant nephrology section chief, Vinaya Rao, M.D., the renal transplant program performs nearly 300 transplants per year, rating it in the top 10 most active transplant programs nationally. The Division now has five transplant nephrologists and one renal transplant fellow. The Division remains one of the most active inpatient consult services, with five services at MUSC and the Ralph H. Johnson VAMC. Under the direction of Milos Budisavljevic M.D., the Division also runs the MUSC Plasmapheresis Unit. Additionally, Zipporah Krishnasami, M.D., and David Ploth, M.D., continue to provide nephrology care, education, and research in Tanzania, Africa. RESEARCH The Division of Nephrology has extremely active bench,
translational, and patient-oriented research programs in autosomal polycystic kidney disease (ADPKD), acute kidney injury, glomerular disease, renal physiology, human and animal genetics, and the role of the renin-angiotensin system in renal disease. Major new funding awarded to Division investigators in FY18 includes the following: • Gary Hardiman, Ph.D., was awarded an NIH UO1 grant to study, “The genetic basis of opioid dependence vulnerability in a rodent model” in collaboration with the MUSC Neuroscience Department. • Daria Ilatovskaya, Ph.D., a new faculty recruit from the University of Wisconsin, received an NIH R00 award, a Polycystic Kidney Disease Foundation award, and an American Physiological Society (APS) Research Career Enhancement award to study the role of sodium in polycystic kidney disease. • Deepak Nihalani, Ph.D., received an NIH R56 award to study, “Preclinical therapeutic validation of a novel therapeutic lead for treating glomerular diseases such as focal and segmental glomerulosclerosis.” EDUCATION In the educational realm, the Nephrology Fellowship Program boasted a successful match of 5/5 fellowship spots for FY18 at a time when 40% of the nation’s training slots were left unfilled.
2018 ANNUAL REPORT
29
PULMONARY, CRITICAL CARE, ALLERGY, & SLEEP MEDICINE
Under the leadership of Lynn Schnapp, M.D., the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine continues to be recognized nationally for excellence in clinical care, cutting-edge research, and innovative educational programs. With a team of nationally renowned faculty, the Division offers a wide range of clinical services, including general and specialized ambulatory clinics, inpatient pulmonary consultation, interventional bronchoscopy, and critical care services. The Division supports a broad-based research enterprise from basic to clinical and translational science, working collaboratively to develop novel therapeutic approaches for the treatment of pulmonary diseases. The Division’s faculty includes numerous NIHfunded, internationally recognized investigators, master clinicians, and award-winning educators. Their awards and accomplishments this year highlight the quality and ingenuity of work done in the Division, both at MUSC and around the world.
30 30
D E PA R T M E N T O F M E D I C I N E
P U L M O N A RY A N D C R I T I C A L C A R E M E D I C I N E
Sections of lung tissue from a patient with idiopathic pulmonary fibrosis (IPF) (left) and a donor without this disease (right). The dark brown color indicates the presence of PDGFRß, a protein characteristic of pericyte cells, and the blue color indicates the nuclei (DNA) of all lung cells. Work in the lab of Lynn Schnapp, M.D., has shown that in IPF, pericytes may convert into cells that contribute to the disease, which is typified by stiffening of the lungs and loss of normal structure.
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL In August 2018, MUSC Health was once again ranked as highperforming in pulmonology by U.S. News & World Report. Under the leadership of Dee Ford, M.D., and Kathryn Cristaldi, M.D. (Pediatrics), MUSC was named one of the first national Telehealth Centers of Excellence in the country by the U.S. Department of Health and Human Services. As a national telehealth coordinating center, MUSC will continue to provide a range of telehealth services at more than 200 locations statewide, leading and modeling the way for health care delivery through advanced technology. Under the leadership of Ennis James, M.D., MUSC was selected as one of 12 international sites to join the Foundation for Sarcoidosis Research Clinical Studies Network. Dr. James and his colleagues at MUSC will collaborate with centers across the world to improve the diagnosis and management of sarcoidosis. RESEARCH Division investigators were successful in obtaining significant extramural funding in FY18. • Under the leadership of Andy Goodwin, M.D., MUSC was selected as a site for the multicenter Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS) study and as a site for the NIH PETAL network to conduct a study comparing Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS). • Additionally, Dr. Goodwin was the recipient of a K23
award to study the role of circulating micro RNAs in ARDS pathogenesis and outcomes. • Nandita Nadig, M.D., was awarded the Society of Critical Care Medicine’s Research Weil Grant, focusing on the impact of inter-ICU transfers on families. EDUCATION The Pulmonary Division was named Division of the Year for the fourth year in a row at the 2018 Internal Medicine Resident Award Day. This past year, the Division initiated a new ABIM Critical Care Fellowship, funded through the VA, and named its first critical care fellow, Olusola Isikalu, M.D., who began the one-year fellowship in July 2018.
Faculty and Staff Awards and Recognition: Nandita Nadig, M.D.: Received the John R. Raymond Mentoring Fellowship in which she will receive focused mentorship by Catherine Hough, M.D., of the University of Washington. Lynn Schnapp, M.D.: Elected as Secretary-Treasurer of the American Thoracic Society (ATS) at the 2018 ATS International Conference and will become ATS President in 2021-22.
2018 ANNUAL REPORT
31
RHEUMATOLOGY & IMMUNOLOGY
The past academic year has been a time of transition for the Division of Rheumatology and Immunology. After 23 years of devoted service to the Division, Rick Silver, M.D., has stepped down as Director. During his tenure, Dr. Silver oversaw the growth of the Division from ten faculty members in 1995 to its present size of 23 faculty members, including 11 clinician scholars and 12 basic scientists. He has helped develop a culture of scholarship, service, and civility and the Division is widely recognized for its strong and integrated programs in clinical care, research, and education. Dr. Silver leaves the Division with a robust research portfolio and two endowed chairs in fibrosis and inflammation held by Carol Feghali-Bostwick, Ph.D., and Betty Tsao, Ph.D. He strengthened the international reputation of the Division in scleroderma research and clinical care and added a lupus focus of research and clinical care that has likewise earned widespread recognition. During Dr. Silver’s 23 years of directorship, the Division of Rheumatology and Immunology has had a committed focus on education with the fellowship program training over 65 fellows, many of whom have gone on to pursue academic careers. At the end of FY18, after a national search, Jim Oates, M.D., was appointed as Division Director. Dr. Oates is a nationally recognized investigator and a leader in lupus research and clinical practice. Moving forward, Dr. Oates envisions the formation of integrated clinical and research centers in scleroderma, lupus, and vasculitis.
32 32
D E PA R T M E N T O F M E D I C I N E
R H E U M ATO LO G Y A N D I M M U N O LO G Y
Jim Oates, M.D.
HIGHLIGHTS & ACCOMPLISHMENTS CLINICAL In August 2018, MUSC Health was ranked at high-performing in rheumatology at 16th in the nation by U.S. News and World Report. It is noteworthy that MUSC Rheumatology has been ranked in the top 20 for the past 10 consecutive years. The Division continues to have a robust clinical presence, and referrals come from across the state, region, and the country. In FY18, approximately 5,400 patients were seen in over 13,000 outpatient visits. The most common diagnosis seen was lupus, followed by non-inflammatory conditions, inflammatory arthritis, and scleroderma. Division providers continue to give expert, compassionate care with the aid of an outstanding staff. RESEARCH The Division maintains a robust research program with a research portfolio totaling $8.9 million in grants and contracts in FY18. New federal and major foundation grants awarded in FY18 highlight the spectrum of the Division’s research activities. These include the following: • Gary Gilkeson, M.D., was awarded a P30 Center grant “Improving Minority Health in Rheumatic Disease (I aM HeaRD)” to serve as a resource for investigations in rheumatic disease with a focus on health disparities.
• Gary Gilkeson, M.D., and Diane Kamen, M.D., received awards from the Lupus Foundation of America and the NIH to perform a multi-center study to determine the effect of and mechanisms behind allogeneic mesenchymal stem cell transplantation on lupus disease activity. • Betty Tsao, Ph.D., was awarded two R01s, one with Jim Oates, M.D., as co-PI. EDUCATION Division faculty continue to be actively engaged in key leadership roles across the institution. These include: Jim Oates, M.D., is the Vice Chair for Research in the Department of Medicine; Rick Silver, M.D., is the Vice Chair for Development in the Department of Medicine; Gary Gilkeson, M.D., is the Associate Dean for Faculty Affairs; Tamara Nowling, Ph.D., serves on the Internal Advisory Board of the MUSC Advancement, Recruitment, and Retention of Women in Science (ARROWS) program; Melissa Cunningham, M.D., Ph.D., Tamara Nowling, Ph.D., and Paula Ramos, Ph.D., serve on the Women Scholars Initiative (WSI) Steering Committee, with Carol Feghali-Bostwick, Ph.D., serving as Chair. Drs. Nowling and Feghali-Bostwick recently published their experience with their focused career development program for women faculty. 2018 ANNUAL REPORT
33
M E D I C A L E D U C AT I O N
Medical Education Residency Leadership E. Benjamin Clyburn, M.D. Program Director
Elizabeth Kirkland, M.D., MSCR Associate Clerkship Director
Kelly Barth, D.O. Medicine/Psychiatry Residency Program Director
Sarah Mennito, M.D., MSCR Medicine/Pediatrics Residency Program Director
Ashley Duckett, M.D. Associate Program Director
Andrew Schreiner, M.D. Associate Program Director
Marc Heincelman, M.D. Clerkship Director
William Shelley, M.D. Associate Program Director
Brad Keith, M.D. Associate Vice Chair, Graduate Medical Education
Internal Medicine Graduating Residents and Education Leadership 2017-2018
34
D E PA R T M E N T O F M E D I C I N E
Internal Medicine Education Staff Missy Atwater Residency Program Coordinator Mary Ann Snell Medical Education Coordinator Meredith Stafford Education Program Coordinator
M E D I C A L E D U C AT I O N
Medical Education The Department of Medicine is deeply committed to the education and training of skilled clinicians, researchers, and educators bound to become the health care leaders of tomorrow. Under the leadership of Benjamin Clyburn, M.D., the Department of Medicine continues to pioneer evidencebased medicine training. With 97 internal medicine resident trainees, and 88 fellows across nine programs, competitive training opportunities span the Department, College of Medicine, and beyond. MUSC’s Internal Medicine Residency program prioritizes collaboration, autonomy, and scholarship, and facilitates learning about highly diverse patients and diseases in a number of practice settings. The Department offers fellowship programs across all nine divisions to provide extraordinary subspecialty training with focus for clinical, clinician-educator, and research careers. The program recruits trainees from the top medical schools and residency programs in the country, and its alumni are among the most distinguished medical professionals in the United States and abroad, including many of the current faculty of MUSC.
2018 Resident Award Day Recipients (listed below)
HIGHLIGHTS & ACCOMPLISHMENTS Our 2017-18 graduates achieved a 95% percent pass rate on the American Board of Internal Medicine (ABIM) Certification Examination.
2018 Resident Award Day Winners Internal Medicine Residency Program:
In 2018, a new Geriatric Medicine Fellowship program received initial accreditation from the ACGME. Under the direction of Mark A. Newbrough, M.D., the one-year program will address a critical need in South Carolina by training physicians to become specialists in the care of older adults.
Intern of the Year: Susan Evenhouse, M.D.
In July 2018, the College of Medicine introduced the new Flex Curriculum that includes an option to complete medical school in three years. Though the three-year option is the most visible change to outsiders, it’s expected to affect only a couple of handfuls of students each year. This effort is part of the medical school’s revised curriculum, which not only gets students started earlier in studying disease and treatment, but also provides opportunities for students to tailor their studies to their interests, whether they are in research, global health, education or medical humanities. And it plans to integrate topics such as telehealth that have been treated as adjuncts in the past.
Attending of the Year (Michael E. Assey Award): Ben Kalivas, M.D., General Internal Medicine
Resident of the Year: Lindsay Helget, M.D., and Maggie Thomas, M.D. (not pictured above) Fellow of the Year: Clark Alsfeld, M.D. (Hematology/ Oncology)
Ambulatory Teacher of the Year: Andrew Schreiner, M.D., General Internal Medicine (not pictured above) Division of the Year: Pulmonary and Critical Care Outpatient Resident of the Year: Michael Whitlow, M.D. Inpatient Resident of the Year: Merle Haulsee, M.D.
2018 ANNUAL REPORT
35
M E D I C A L E D U C AT I O N
Internal Medicine Housestaff Internal Medicine Chief Residents (left)
Kevin Baker, M.D., VA Chief Ryan Miller, M.D. Carley Mills, M.D. (not pictured) Andy Nielsen, M.D.
PGY-1 Interns
Ahmad Aleisa, M.D. (Prelim) Poorva Apte, M.D. Eliza Barnwell, M.D. (Prelim) Travis Benzing, M.D. Laurel Branch, M.D. Leah Broadhurst, M.D. (Med-Peds) Laura Brown, M.D. (Med-Peds) Zane Chiad, M.D. Sam Dickey, M.D. Lisa Edwards, M.D. (Prelim) Milad El Hajj, M.D. Lee Ellison, M.D. Jessica English, M.D. Susan Evenhouse, M.D. (Med-Peds) Sam Friedman, M.D. Joseph Golden, M.D. Paterson Graham, M.D. Allison Hajec, M.D. William Harvey, M.D. Hallie Hinen, M.D. (Prelim) Isaac Jaben, M.D. Abid Javed, M.D. James Kalmuk, M.D. Shadi Khalil, M.D. Ricky Lueking, M.D. Steven Maurides, M.D. Margaret Morrison, M.D. Karan Pandya, M.D. Louisa Phillips, M.D. (Prelim) Chelsea Shepherd, M.D. (Med-Psych) John Smith, M.D. (Med-Psych) Patricia Smith, M.D. (Med-Peds) Brett Tomashitis, M.D. Nishant Trivedi, M.D. Cameron Wilhoit, M.D. 36
D E PA R T M E N T O F M E D I C I N E
PGY-2 Residents
Samuel Abbas, M.D. Chris Armstrong, M.D. Ben Barnette, M.D. Devin Blankinship, M.D. Jack Bridges, M.D. Neelam Chaudhary, M.D. Kimberley Davenport, M.D. Kevin Douglass, M.D. Edward Drehs, M.D. Travis Ferguson, M.D. Lindsay Helget, M.D. Andrea James, M.D. Carson Keck, M.D. John LeCluyse, M.D. Ben Long, M.D. Cam Mateus, M.D. (Med-Psych) George Mawardi, M.D. Jose Mira, M.D. Prabodh Mishra, M.D. Shuaib Mohammad, M.D. Mike Norred, M.D. (Med-Psych) Callie Osborne, M.D. Malshundria Prophet, M.D. Prashant Raghavendran, M.D. (Med-Peds) Chris Rangel, M.D. Jen Schmidt, M.D. Rani Shayto, M.D. Maggie Thomas, M.D. Mason Walgrave, M.D. (Med-Peds)
PGY-3 Residents
Michael Adams, M.D. Mark Brodie, M.D. Sarah Compton, M.D. Dustin Dalton, M.D. Dustin Fowler, M.D. (Med-Peds) Katalina Funke, M.D., MS Kevin Gao, M.D. Max Gevedon, M.D. Laurie Graves, M.D. (Med-Peds) Mandev Guram, M.D. Merle Haulsee, M.D. Emily Hodskins, M.D. Matthew Jaenicke, M.D. Boris Kiselev, M.D. (Med-Psych) Sarah Knapp, M.D. Nila Manandhar, M.D. Andrew McNulty, M.D. Thomas Miller, M.D. Morgan Randall, M.D. Matthew Rolfsen, M.D. Eric Sellers, M.D. Manasi Singh, MBBS Michelle Spiegel, M.D. Margaret Stafford, M.D. Mary Stoermann, M.D. (Med-Psych) Daphanie Taylor, M.D. Michael Whitlow, M.D. Alex Zhadkevich, M.D.
PGY-4/PGY-5 Residents
Jay Glenn, M.D. (Med-Psych) Kathleen Head, M.D. (Med-Peds) Mithunan Maheswaranathan, M.D. (Med-Peds) Sarah Oros, M.D. (Med-Psych) Allison Smith, M.D. (Med-Psych)
M E D I C A L E D U C AT I O N
Subspecialty Fellows Cardiology
Mazahir Alimohamed, M.D. Brian Blaker, M.D. Ross Butschek, M.D. Amanda Cai, M.D. Christopher Capps, M.D. David De Maria, M.D. Laura Divoky, M.D., MPH Stephanie El Hajj, M.D. Will Halligan, M.D. Daniel Hobbs, M.D. Leah John, M.D. Reza Karimianpour, D.O. Sofy Landes, M.D. Amanda Northup, M.D. Norman (Brad) Stevens, M.D. Ashley Waring, M.D. William Wheeler, III, M.D. Jeffrey Yourshaw, M.D.
Interventional Cardiology
Dean Abtahi, M.D. Tariq Hameed, M.D.
Electrophysiology Cardiology
Daniel Cobb, M.D. Scott Koerber, D.O. J. Alvin Kpaeyeh, M.D. Thomas Turnage, M.D.
Endocrinology
Rashi Agarwal, M.D. Elizabeth Bond, D.O. Zainab Mian, M.D. Shashpal, M.D.
Gastroenterology and Hepatology
Mustafa Ali Abdul-Hussein, M.D. Heather Barton, M.D. Kevin Batte, M.D. Derek Feussner, M.D. Caitlin Green, M.D. Nathan Holman, M.D. Nicolas Labarre, M.D. Andy Maldonado, M.D. Lance McLeroy, M.D. Richard Schatz, M.D. Akshay Shetty, M.D. Clayton Spiceland, M.D.
Hematology/Oncology
Leonard Alsfeld, M.D. Joe Collins, M.D., MPH Anshu Giri, M.D. Pannaga Malalur, MBBS Joshua Mansour, M.D. Sara Matar, M.D. Sandra Mazzoni, D.O Jenny McCallister Riley, M.D. Hammad Shafqat, M.D. Darion Showell, D.O. Woody Xiao, M.D., MPH
Infectious Diseases
Eunice Guzman, M.D. Robert Jakubowski, M.D. Shruti Puri, M.D. Talha Riaz, M.D. Hilary Steele, M.D.
Nephrology
Prince Amaechi, M.D. Waleed Asfar, M.D. Jorge Chabrier-Rosello, M.D. Angela Dillon, M.D. Andrew Elliott, D.O. Fredrik Jenssen, M.D. Anna Marshall, D.O. Keisuke Okamoto, M.D. Hardik Patel, M.D. Adam Price, M.D. Harol Valenzuela, M.D.
Pulmonary and Critical Care Haitham Al Ashry, MBChB Emerald Banas, M.D. Ben Bevill, M.D. Brad Brasher, M.D. Nick Fox, M.D. Todd Gandy, M.D. Maroun Ghossein, M.D., MPH Nathan Hill, M.D. Daniel Hynes, M.D. Adam Kouns, M.D. Branden Luna, D.O. Brad Petkovich, M.D. Mario Ponce, M.D. Angelina Somoracki, D.O., MPH Nina Thomas, M.D.
Rheumatology and Immunology Deanna Baker-Frost, M.D., Ph.D. Stephen Elmore, M.D. Jamie Latos, D.O. Forrest Powers, M.D. Hayley Walter, M.D.
2018 ANNUAL REPORT
37
D E V E LO P M E N T
Philanthropy GRATEFUL FOR YOUR GIFTS In today’s scientifically-advanced medical environment, gifts from donors have never been more critical to enabling MUSC to achieve its mission of providing extraordinary care and engaging in research that benefits the Charleston community and beyond. Because of gifts from donors, MUSC can recruit the highest quality physicians, faculty, and scientists who are doing vital research that promises better therapies and outcomes for so many. The Department of Medicine is deeply appreciative of the donors who have compassionately invested in the people and programs at MUSC. A major priority for the Department of Medicine is to develop endowed chairs. Currently, the Department has four endowment campaigns underway to honor the gifted teaching and outstanding medical care provided by faculty members. Once established, these endowments will confer academia’s highest honor upon our most accomplished medical scientists and educators and will serve as a permanent resource supporting medical education, cutting-edge research, and patient care.
(L-R): Richard Silver, M.D., with patients Haylee and Kaylee Thomas.
CURRENT PHILANTHROPIC PRIORITIES
$1,000,000 Goal
$914,677 Raised
$500,000 Goal
$485,638 Raised
38
D E PA R T M E N T O F M E D I C I N E
Richard M. Silver, M.D., Endowed Chair
Honoring his compassion and commitment: The Department of Medicine established the Richard M. Silver, M.D., Endowed Chair to honor Dr. Silver’s significant contributions to the field of rheumatology at MUSC, his compassion for his patients, and his unwavering dedication and commitment to training the next generation of physician-scientists. Thus far, donors have generously provided $914,677 of the $1,000,000 goal.
Jay Brzezinski, M.D., Clinical Educator Professorship
Impacting the lives of countless students: Dr. Jay Brzezinski has been an esteemed teacher, physician, mentor, and friend to countless MUSC medical students and patients since he came to MUSC in 1987. The Department of Medicine established the Jay Brzezinski, M.D., Clinical Educator Professorship to honor Dr. Brzezinski’s exemplary career and his dedication to academic medicine. The professorship will provide support for a faculty member who has demonstrated excellence in teaching. To date, loyal and generous donors have provided $485,638 of the $500,000 goal.
D E V E LO P M E N T
$1,000,000 Goal
$411,885 Raised
$1,000,000 Goal
$387,823 Raised
Donald O. Castell, M.D., Endowed Chair
“Don is what the best of teachers and mentors strive to be. He perfected the art of educating and building the next generation of physicians and clinical researchers.” —Amine Hila, M.D. The tribute above is one of many that Dr. Castell received from former trainees and colleagues who have worked with and learned from him over the years. The wonderful tributes are testaments to Castell’s outstanding contributions to the field of gastroenterology and to his gifted teaching. To honor his outstanding career, the Department of Medicine established the Donald O. Castell, M.D., Endowed Chair in Gastroenterology. Thus far, donors have generously provided $411,885 of the $1,000,000 goal.
J. Michael Kilby, M.D., Endowment
“Michael was an incredibly gifted clinician, teacher, and mentor and wore his heart on his sleeve. Infectious disease at MUSC wishes to remember and celebrate a true ambassador of the specialty.” —Cassandra Salgado, M.D. The J. Michael Kilby, M.D., Endowment was established in memory of Dr. Kilby with the long-term goal of creating an endowed chair, the most coveted and highly esteemed legacy possible at MUSC. Contributions to this meaningful tribute campaign will support the Infectious Diseases Division, help establish a permanent fund in support of its educational, research, and clinical programs, and enable the Division to continue the compassionate work for which Dr. Kilby was known and loved. To date, donors have generously provided $387,823 of the $1,000,000 goal.
YOUR GIFTS ARE HELPING TO PROVIDE A BRIGHTER FUTURE FOR PATIENTS Haylee and Kaylee Thomas (shown top left) are twin sisters who developed juvenile idiopathic arthritis at a very young age. Haylee and Kaylee have been patients of Richard Silver, M.D., Distinguished University Professor in the Division of Rheumatology and Immunology, since they were first-graders. Now sophomores at Coastal Carolina University, they are excelling academically and are Dean’s List honorees. With the advances in medical therapy and the outstanding care offered by members of the Department of Medicine, Haylee and Kaylee and other patients with complex medical illnesses can look forward to a very bright future.
Support the Department of Medicine There are many philanthropic opportunities to support our mission, and each gift to the Department makes an impact on our daily efforts. We hope that you will partner with us to advance education, expand research, and improve excellence in patient care. Please contact Nat Howe, Director of Development, at 843-792-4280, howen@ musc.edu or visit musc.edu/giving/ medicine.
2018 ANNUAL REPORT
39
D E V E LO P M E N T
Changing What's Possible – Development Highlights Meet One of Our Newest Leaders: Nat Howe, Director of Development Please join us in welcoming Nat Howe as the new Director of Development for the Department of Medicine. Nat has 20 years of fundraising and development experience in academic institutions, including leadership roles at both the elementary and university levels. Nat is joining us from Princeton University where he most recently served as Senior Associate Director in the Annual Giving Office. His extensive experience, skill sets, and leadership qualities will be of great value to the Department and we are excited to have Nat join the team. Please join us in welcoming Nat Howe to Charleston and the MUSC Community! For more information, contact Nat Howe, Director of Development, at 843-792-4280 or howen@musc.edu, or visit musc.edu/ giving/medicine.
Nat Howe
“I am looking forward to working with the staff, friends, and benefactors of MUSC, whom I know already enjoy a tremendous working relationship with the Department of Medicine and have generously contributed to the Department’s philanthropic efforts in the past” —Nat Howe
MUSC Awards New Endowed Chair in the Division of Cardiology Jeffrey Winterfield, M.D., Associate Professor of Cardiac Electrophysiology in the Division of Cardiology, has been named as the Hank and Laurel Greer Chair in Cardiac Electrophysiology. To be appointed as an Endowed Chair is highest honor that the University can bestow upon a faculty member. This prestigious title extends further than just another line on a letterhead, but acts as a recognition of the important, and unique, contributions brought by the holder and namesake. 40
D E PA R T M E N T O F M E D I C I N E
Dr. Winterfield has special expertise in catheter ablation of arrhythmias on the outside of the heart (epicardial VT). He cares for adult patients with cardiac rhythm disturbances including supraventricular tachycardia (SVT), Wolf-Parkinson-White (WPW), atrial fibrillation (AF), as well as premature ventricular contractions (PVCs), and ventricular tachycardia (VT). The Hank and Laurel Greer Chair in Cardiac Electrophysiology was established through an estate gift as well as a current philanthropic gift from the Greers.
E M P LOY E E R E C O G N I T I O N
Employee Recognition
Department of Medicine Employee Recognition Program
The Department would like to recognize all of our Employee of the Quarter winners for FY2018.
The Department of Medicine Employee of the Quarter program was established to showcase employees who have shown exemplary strides in contributing to the Department of Medicine and to the MUSC community. Nominees consistently demonstrate exceptional service, commitment to job excellence, innovation and initiative, and go above and beyond the call of duty. At the end of the year, an Employee of the Year winner and Medicine Excellence winner (runner-up) are selected from the group of quarterly winners.
Michelle Duenas Gastroenterology and Hepatology Deborah Everidge Cardiology Michelle Forster Medicine Administration Cameron Hay Pulmonary and Critical Care Sandra Hurley Nephrology Justin Marsden General Internal Medicine Megan Ohorodnyk Infectious Diseases Abbi Reed Pulmonary and Critical Care Yingyu Ren Gastroenterology and Hepatology Christy Reuben Hematology and Oncology
(L-R): Don Rockey, M.D., Rebekah Shinta, Brian Vaughters, Georgia Brogdon
The Department of Medicine is pleased to announce the Employee of the Year and Medicine Excellence Award winners for FY2018.
Employee of the Year Rebekah Shinta Division Administrator, Infectious Diseases, Rheumatology & Immunology, Director, Grants Administration
Angela Robinson Rheumatology and Immunology Rebekah Shinta Infectious Diseases; Rheumatology and Immunology Chris Skope Infectious Diseases Mary Ann Snell Medicine Administration
Medicine Excellence Winner
Brian Vaughters Medicine Administration
Brian Vaughters Accountant/Fiscal Analyst, Medicine Administration
Danielle Woodford Pulmonary and Critical Care 2018 ANNUAL REPORT
41
RESEARCH FUNDING HIGHLIGHTS
New Extramural Research Funding Highlights FY18
principal investigators
extramural sponsors
award date
Dr. Don Rockey
NIH/NIDDK
October 4, 2017
Dr. Patrick Mauldin
Health Sciences SC
October 17, 2017
Novel Biomarkers to Shorten TB Treatment
Dr. Susan Dorman
Rutgers University
January 22, 2018
Tuberculosis Trial Consortium of the US Centers for Disease Control and Prevention (TBTC)
Dr. Susan Dorman
Department of Veterans Affairs
May 22, 2018
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis
Dr. Susan Dorman
NIH/NIAID
February 15, 2018
Multi-Disciplinary Clinical Research and Mentoring in Tuberculosis Diagnositcs
Dr. Susan Dorman
NIH/NIAID
November 1, 2017
Dr. Daria Ilatovskaya
NIH/NIDDK
February 15, 2018
Telehealth Center of Excellence
Dr. Dee Ford
HRSA
March 26, 2018
The Role of Circulating Micro RNAs in ARDS Pathogenesis and Outcomes
Dr. Andrew Goodwin
NIH/NHLBI
July 26, 2017
The Psychological Impact of Inter-ICU Transfers
Dr. Nandita Nadig
Society of Critical Care Medicine
April 18, 2018
research grant title
Gastroenterology and Hepatology A Molecular Approach to the Pathogenesis of Portal Hypertension
General Internal Medicine South Carolina Surgical Quality Collaborative
Infectious Diseases
Nephrology The Involvement of ATP-Dependent Inhibition of ENaC in ARPKD Cystogenesis
Pulmonary, Critical Care, Allergy, and Sleep Medicine
42
D E PA R T M E N T O F M E D I C I N E
RESEARCH FUNDING HIGHLIGHTS
New Extramural Research Funding Highlights FY18
principal investigators
extramural sponsors
award date
Dr. Lynn Schnapp
NIH/NHLBI
August 16, 2017
Improving Minority Health in Rheumatic Disease (I aM HeaRD)
Dr. Gary Gilkeson
NIH/NIAMS
October 16, 2017
Antifibrotic Effects of Dabigatran in Scleroderma Patients
Dr. Richard Silver
Scleroderma Foundation
April 24, 2018
Transancestral Fine Mapping and Functional Dissection of Autophagy-Related SLE Risk Loci
Dr. Betty Tsao
NIH/NIAMS
April 30, 2018
research grant title
Pulmonary, Critical Care, Allergy, and Sleep Medicine Role of Pericytes in Scleroderma Skin and Lung Fibrosis
Rheumatology and Immunology
Department of Medicine FYTD Research Expenses $30,000,000 $25,000,000 $20,000,000 $15,000,000 $10,000,000
$21.3 M
$24.3 M
$25.1 M
$26.1 M
$5,000,000 $0
FY2015
FY2016
FY2017
FY2018
2018 ANNUAL REPORT
43
P U B L I C AT I O N S
Selected Publications: FY18 Cardiology
DeLeon-Pennell KY, Iyer RP, Ma Y, Yabluchanskiy A, Zamilpa R, Chiao YA, Cannon P, Cates C, Flynn ER, Halade GV, de Castro Bras LE, Lindsey ML. The mouse heart attack research tool (mHART) 1.0 database. Am J Physiol Heart Circ Physiol. 2018 May 18. Essandoh MK, Mark GE, Aasbo JD, Joyner CA, Sharma S, Decena BF, Bolin ED, Weiss R, Burke MC, McClernon TR, Daoud EG, Gold MR. Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. Pacing Clin Electrophysiol. 2018 May 13. Inuzuka R, Hsu S, Tedford RJ, Senzaki H. Single-beat estimation of right ventricular contractility and its coupling to pulmonary arterial load in patients with pulmonary hypertension. J Am Heart Assoc. 2018 May 8;7(10). Kimbrough D, Wang SH, Wright LH, Mani SK, Kasiganesan H, LaRue AC, Cheng Q, Nadig SN, Atkinson C, Menick DR. HDAC inhibition helps post-MI healing by modulating macrophage polarization. J Mol Cell Cardiol. 2018 Jun;119:51-63.
Endocrinology
Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, Virella G, LopesVirella MF; DCCT/EDIC Research Group. Association between inflammatory markers and progression to kidney dysfunction: examining different assessment windows in patients with type 1 diabetes. Diabetes Care. 2018 Jan;41(1):128-135. Basu A, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Schade DS, Wood J, Alaupovic P, Lyons TJ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res. 2018 May;59(5):872-883. Hunt KJ, Jaffa MA, Garrett SM, Luttrell DK, Lipson KE, Lopes-Virella MF, Luttrell LM, Jaffa AA; VADT Investigators. Plasma Connective Tissue Growth Factor (CTGF/CCN2) levels predict myocardial infarction in the Veterans Affairs Diabetes Trial (VADT) cohort. Diabetes Care. 2018 Apr;41(4):840-846.
Jin J, Lu Z, Li Y, Cowart LA, Lopes-Virella MF, Huang Y. Docosahexaenoic acid antagonizes the boosting effect of palmitic acid on LPS inflammatory signaling by inhibiting gene transcription and ceramide synthesis. PLoS One. 2018 Feb 23;13(2).
McDonald LT, Zile MR, Zhang Y, Van Laer AO, Baicu CF, Stroud RE, Jones JA, LaRue AC, Bradshaw AD. Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis. Am J Physiol Heart Circ Physiol. 2018 Jul 1;315(1):H92-H100. Meinel FG, Schoepf UJ, Townsend JC, Flowers BA, Geyer LL, Ebersberger U, Krazinski AW, Kunz WG, Thierfelder KM, Baker DW, Khan AM, Fernandes VL, O'Brien TX. Diagnostic yield and accuracy of coronary CT angiography after abnormal nuclear myocardial perfusion imaging. Sci Rep. 2018 Jun 15;8(1):9228. O'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon SD, Packer M, McMurray JJV, Zile MR. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 May;11(5). Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. Tampakakis E, Shah SJ, Borlaug BA, Leary PJ, Patel HH, Miller WL, Kelemen BW, Houston BA, Kolb TM, Damico R, Mathai SC, Kasper EK, Hassoun PM, Kass DA, Tedford RJ. Pulmonary effective arterial elastance as a measure of right ventricular afterload and its prognostic value in pulmonary hypertension due to left heart disease. Circ Heart Fail. 2018 Apr;11(4):e004436.
Yourshaw JP, Mishra P, Armstrong MC, Ramu B, Craig ML, Van Bakel AB, Steinberg DH, DiSalvo TG, Tedford RJ, Houston BA. Effects of percutaneous LVAD support on right ventricular load and adaptation. J Cardiovasc Transl Res. 2018 Apr 30. Pictured: Brian Houston, M.D.
44
D E PA R T M E N T O F M E D I C I N E
Pictured: Yan Huang, M.D., Ph.D. Kelly CB, Hookham MB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Menard MK, Aston CE, Lyons TJ. Response to comment on Kelly et al. Subclinical first trimester renal abnormalities are associated with preeclampsia in normoalbuminuric women with type 1 diabetes. Diabetes Care 2018;41:120-127. Diabetes Care. 2018 Jun;41(6):e102-e103. Kelly CB, Hookham MB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Menard MK, Aston CE, Lyons TJ. Subclinical first trimester renal abnormalities are associated with preeclampsia in normoalbuminuric women with type 1 diabetes. Diabetes Care. 2018 Jan;41(1):120-127. Lu Z, Li Y, Brinson CW, Lopes-Virella MF, Huang Y. Cooperative stimulation of atherogenesis by lipopolysaccharide and palmitic acid-rich high fat diet in lowdensity lipoprotein receptor-deficient mice. Atherosclerosis 265:231-241, 2017. Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, Li Y, Chassereau C, Huang Y, Lopes-Virella MF. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clinical Immunology 187:1-9, 2017.
Gastroenterology
Brodie MM, Newman JC, Smith T, Rockey DC. Severity of gastrointestinal bleeding in patients treated with direct-acting oral anticoagulants. Am J Med. 2018 May;131(5):573.e9-573.e15. Cotton PB, Suarez AL, Cunningham SC, Pauls Q, Bingener J, Morgan K. How much pain relief do patients expect after cholecystectomy? Surg Endosc. 2018 Apr;32(4):1867-1870.
P U B L I C AT I O N S
Selected Publications: FY18
Ercan-Fang NG, Rockey DC, Dine CJ, Chaudhry S, Arayssi T. Resident research experiences in internal medicine residency programs-a nationwide survey. Am J Med. 2017 Dec;130(12):1470-1476.
Kinfe G Bishu, Edward Lahiff, Seamus O’Reilly, Mulugeta Gebregziabher. Drivers of farmers’ cattle insurance decisions: evidence from smallholders in northern Ethiopia. Agrekon. 2018; 57(1):40-48.
Haj M, Hart M, Rockey DC. Development of a novel clinical staging model for cirrhosis using the nationwide inpatient sample. J Investig Med. 2018 Aug;66(6):992-997.
Kirkland E, Zhang J, Brownfield E, Heincelman M, Schumann S, Schreiner A, Bishu K, Mauldin PD, Moran WP. Sustained improvement in blood pressure control for a multiracial cohort: results of a patient-centered medical home quality improvement initiative. Quality in Primary Care. 2017 25 (5): 297-302.
Maheswaranathan M, Ngo T, Rockey DC. Identification and management of the hypervirulent invasive klebsiella pneumoniae syndrome: a unique and distinct clinical entity. J Investig Med High Impact Case Rep. 2018 Oct 16;6. Manka P, Coombes JD, Boosman R, Gauthier K, Papa S, Syn WK. Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment. Cancer Lett. 2018 Apr 10;419:175-186.
Shi Z, Rockey DC. Upregulation of the actin cytoskeleton via myocardin leads to increased expression of type 1 collagen. Lab Invest. 2017 Dec;97(12):1412-1426. Pictured: Zengdun Shi, M.D. Suarez AL, Xu H, Cotton PB, Elmunzer BJ, Adams D, Morgan KA, Sheafor D, Coté GA. Trends in the timing of inpatient ERCP relative to cholecystectomy: a nationwide database studied longitudinally. Gastrointest Endosc. 2018 Sep;88(3):502-510.
Kirkland EB, Heincelman M, Bishu KG, Schumann SO, Schreiner A, Axon RN, Mauldin PD, Moran WP. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003-2014. J Am Heart Assoc. 2018 May 30;7(11). Lekoubou A, Bishu KG, Ovbiagele B. Nationwide impact of the 2017 American College of Cardiology/American Heart Association blood pressure guidelines on stroke survivors. J Am Heart Assoc. 2018 Jun 6;7(12). Schreiner AD, Mauldin PD, Moran WP, Durkalski-Mauldin V, Zhang J, Schumann SO 3rd, Heincelman ME, Marsden J, Rockey DC. Assessing the burden of abnormal LFTs and the role of the electronic health record: a retrospective study. Am J Med Sci. 2018 Jun;355(6):537-543.
Schreiner AD, Moran WP, Zhang J, Kirkland EB, Heincelman ME, Schumann Iii SO, Mauldin PD, Rockey DC. Evaluation of liver test abnormalities in a patient-centered medical home: do liver test patterns matter? J Investig Med. 2018 Jun 25. Pictured: Andrew Schreiner, M.D.
Thomas A, Koch D, Marsteller W, Lewin D, Reuben A. An analysis of the clinical, laboratory, and histological features of striped, punctate, and nodular gastric antral vascular ectasia. Dig Dis Sci. 2018 Apr;63(4):966-973.
Schreiner AD, Zhang J, Bian J, Schumann SO, Kirkland E, Mauldin PD, WP Moran. Trends in follow-up liver chemistry testing: a retrospective cohort study. Quality in Primary Care. 2018 26 (1): 20-22.
Wuerth BA, Rockey DC. Changing epidemiology of upper gastrointestinal hemorrhage in thelast decade: a nationwide analysis. Dig Dis Sci. 2018 May;63(5):1286-1293.
Hematology/Oncology
General Internal Medicine
Bian J, Schreiner AD, Zhang J, Schumann SO, Rockey DC, Mauldin PD, Moran WP. Associations of race with follow-up patterns after initial abnormal liver tests in primary care. J Gen Intern Med. 2018 Jun 22. Gebregziabher M, Ward RC, Taber DJ, Walker RJ, Ozieh M, Dismuke CE, Axon RN, Egede LE. Ethnic and geographic variations in multimorbidty: evidence from three large cohorts. Soc Sci Med. 2018 Aug;211:198-206. Heincelman M, Duckett A, Keith B, Schreiner A, Zhang J, Kilb E, Clyburn B. The structure of medical intensive care units at training institutions. Am J Med Sci. 2018 Apr;355(4):396-401.
Britten CD, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, Brisendine A, Anderton K, Cusack SL, Maines LW, Zhuang Y, Smith CD, Thomas MB. A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017 Aug15;23(16):4642-4650. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 May 24. Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP. IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res. 2018 Feb;38(2):45-68.
Hunt KJ, Gebregziahber M, Everett CJ, Heidenreich PA, Axon RN. The interaction between rural/urban status and dual use status among veterans with heart failure. Rural Remote Health. 2018 May;18(2):4495.
2018 ANNUAL REPORT
45
P U B L I C AT I O N S
Selected Publications: FY18 Hematology/Oncology Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a nonrandomised, open-label, phase 1b trial. Lancet Oncol. 2018 May;19(5):694-704. Pictured: John Wrangle, M.D.
Infectious Diseases
Jakubowski R, Steed LL, Dorman SE, Marculescu C. A case of malaria predisposing to salmonella bacteremia in a returning traveler from Nigeria. Case Rep Infect Dis. 2018 Sep 27;2018.
Tolson C, Richey LE, Zhao Y, Korte JE, Brady K, Haynes L, Meissner EG. Association of substance use with hospitalization and virologic suppression in a southern academic HIV clinic. Am J Med Sci. 2018 Jun;355(6):553-558. Pictured: Eric Meissner, M.D., Ph.D. Xie YL, Cronin WA, Proschan M, Oatis R, Cohn S, Curry SR, Golub JE, Barry Iii CE, Dorman SE. Transmission of mycobacterium tuberculosis from patients who are nucleic acid amplification test- negative. Clin Infect Dis. 2018 Apr 24. Zhou Z, Powell AM, Ramakrishnan V, Eckard A, Wagner C, Jiang W. Elevated systemic microbial translocation in pregnant HIV-infected women compared to HIV-uninfected women, and its inverse correlations with plasma progesterone levels. J Reprod Immunol. 2018 Jun;127:16-18.
Nephrology
Lee HW, Arif E, Altintas MM, Quick K, Maheshwari S, Plezia A, Mahmood A, Reiser J, Nihalani D, Gupta V. High-content screening assay-based discovery of paullones as novel podocyte-protective agents. Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F280-F292.
Mwasongwe SE, FĂźlĂśp T, Katz R, Musani SK, Sims M, Correa A, Flessner MF, Young BA. Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study. J Clin Hypertens (Greenwich). 2018 Apr;20(4):775-783. Ploth DW, Mbwambo JK, Fonner VA, Horowitz B, Zager P, Schrader R, Fredrick F, Laggis C, Sweat MD. Prevalence of CKD, diabetes, and hypertension in rural Tanzania. Kidney Int Rep. 2018 Apr 22;3(4):905-915. Prince LK, Campbell RC, Gao SW, Kendrick J, Lebrun CJ, Little DJ, Mahoney DL, Maursetter LA, Nee R, Saddler M, Watson MA, Yuan CM; Nephrology Education Research & Development Consortium. The dialysis orders objective structured clinical examination (OSCE): a formative assessment for nephrology fellows. Clin Kidney J. 2018 Apr;11(2):149-155. Sagar A, Arif E, Solanki AK, Srivastava P, Janech MG, Kim SH, Lipschutz JH, Kwon SH, Ashish, Nihalani D. Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function. Sci Rep. 2017 Sep 21;7(1):12047. Shi Y, Obert E, Rahman B, Rohrer B, Lobo GP. The Retinol Binding Protein Receptor 2 (Rbpr2) is required for photoreceptor outer segment morphogenesis and visual function in zebrafish. Sci Rep. 2017 Nov 24;7(1):16207. Shi Y, Su Y, Lipschutz JH, Lobo GP. Zebrafish as models to study ciliopathies of the eye and kidney. Clin Nephrol Res. 2017 Dec;1(1):6-9. Shuyskiy LS, Levchenko VV, Negulyaev YuA, Staruschenko A, Ilatovskaya DV. The role of adapter protein MIM in actin-dependent regulation of the epithelial Na+ channel (ENaC). (2018) Acta Naturae. 10(2):97-103. Solanki AK, Arif E, Morinelli T, Wilson RC, Hardiman G, Deng P, Arthur JM, Velez JC, Nihalani D, Janech MG, Budisavljevic MN. A novel CLCN5 mutation associated with focal segmental glomerulosclerosis and podocyte injury. Kidney Int Rep. 2018 Jun 18;3(6):1443-1453. Velez JCQ, Arif E, Rodgers J, Hicks MP, Arthur JM, Nihalani D, Bruner ET, Budisavljevic MN, Atkinson C, Fitzgibbon WR, Janech MG. Deficiency of the angiotensinase aminopeptidase a increases susceptibility to glomerular injury. J Am Soc Nephrol. 2017 Jul;28(7):2119-2132.
Lobo GP, Fulmer D, Guo L, Zuo X, Dang Y, Kim SH, Su Y, George K, Obert E, Fogelgren B, Nihalani D, Norris RA, Rohrer B, Lipschutz JH. The exocyst is required for photoreceptor ciliogenesis and retinal development. J Biol Chem. 2017 Sep 8;292(36):14814-14826.
Pulmonary and Critical Care
Pictured: Glenn Lobo, Ph.D.
Bade BC, Hyer JM, Bevill BT, Pastis A, Rojewski AM, Toll BA, Silvestri GA. A patient-centered activity regimen improves participation in physical activity interventions in advanced-stage lung cancer. Integr Cancer Ther. 2018 Sep;17(3):921-927.
Lobo GP, Pauer G, Lipschutz JH, Hagstrom SA. The Retinol-Binding Protein Receptor 2 (Rbpr2) is required for photoreceptor survival and visual function in the zebrafish. Adv Exp Med Biol. 2018;1074:569-576.
46
McMahon BA, Koyner JL, Novick T, Menez S, Moran RA, Lonze BE, Desai N, Alasfar S, Borja M, Merritt WT, Ariyo P, Chawla LS, Kraus E. The prognostic value of the furosemide stress test in predicting delayed graft function following deceased donor kidney transplantation. Biomarkers. 2018 Feb;23(1):61-69.
D E PA R T M E N T O F M E D I C I N E
Bade BC, Brooks MC, Nietert SB, Ulmer A, Thomas DD, Nietert PJ, Scott JB, Silvestri GA. Assessing the correlation between physical activity and quality of life in advanced lung cancer. Integr Cancer Ther. 2018 Mar;17(1):73-79.
P U B L I C AT I O N S
Selected Publications: FY18 Pulmonary and Critical Care Beiko T, Janech MG, Alekseyenko AV, Atkinson C, Coxson HO, Barth JL, Stephenson SE, Wilson CL, Schnapp LM, et al. Serum proteins associated with emphysema progression in severe alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):204-216. Pictured: Tatsiana Beiko, M.D., MSCR
Tanner NT, Porter A, Gould MK, Li XJ, Vachani A, Silvestri GA. Physician assessment of pretest probability of malignancy and adherence with guidelines for pulmonary nodule evaluation. Chest. 2017 Aug;152(2):263-270. VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017 Sep;16(5):607-615.
Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 Jan;17(1):83-88.
West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators. Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep;16(5):600-606.
Flume PA, Winthrop KL. Mycobacterial disease: evolving concepts. Semin Respir Crit Care Med. 2018 Jun;39(3):269.
Rheumatology and Immunology
Foil KE, Blanton MG, Sanders C, Kim J, Al Ashry HS, Kumbhare S, Strange C. Sequencing alpha-1 MZ individuals shows frequent biallelic mutations. Pulm Med. 2018 Sep 5;2018:2836389. Furukawa BS, Pastis NJ, Tanner NT, Chen A, Silvestri GA. Comparing pulmonary nodule location during electromagnetic bronchoscopy with predicted location on the basis of two virtual airway maps at different phases of respiration. Chest. 2018 Jan;153(1):181-186. Goodwin AJ, Ford DW. Readmissions among sepsis survivors: risk factors and prevention. Clin Pulm Med. 2018 May;25(3):79-83. Hung CF, Wilson CL, Chow YH, Schnapp LM. Role of integrin alpha8 in murine model of lung fibrosis. PLoS One. 2018 May 29;13(5). James WE, Koutroumpakis E, Saha B, Nathani A, Saavedra L, Yucel RM, Judson MA. Clinical features of extrapulmonary sarcoidosis without lung involvement. Chest. 2018 Aug;154(2):349-356. Rojewski AM, Tanner NT, Dai L, Ravenel JG, Gebregziabher M, Silvestri GA, Toll BA. Tobacco dependence predicts higher lung cancer and mortality rates and lower rates of smoking cessation in the national lung screening trial. Chest. 2018 Jul;154(1):110-118. Schutt SD, Wu Y, Tang CH, Bastian D, Nguyen H, Sofi MH, Zhang M, Liu C, Helke K, Wilson C, Schnapp LM, Del Valle JR, Hu CC, Yu XZ. Inhibition of the IRE-1Îą/ XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice. Blood Adv. 2018 Feb 27;2(4):414-427. Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. Chest. 2018 Sep;154(3):491-500. Stephenson SE, Wilson CL, Crothers K, Attia EF, Wongtrakool C, Petrache I, Schnapp LM. Impact of HIV infection on Îą(1)-antitrypsin in the lung. Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L583-L592. Tanner NT, Dai L, Bade BC, Gebregziabher M, Silvestri GA. Assessing the generalizability of the national lung screening trial: comparison of patients with stage 1 disease. Am J Respir Crit Care Med. 2017 Sep 1;196(5):602-608.
Akter T, Atanelishvili I, Noguchi A, Silver RM, Bogatkevich GS. Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10. PLoS One. 2017 Nov 27;12(11). Kortemeier E, Ramos PS, Hunt KJ, Kim HJ, Hardiman G, Chung D. ShinyGPA: An interactive visualization toolkit for investigating pleiotropic architecture using GWAS datasets. PLoS One. 2018 Jan 8;13(1). Ozen G, Kamen DL, Mikuls TR, England BR, Wolfe F, Michaud K. Trends and determinants of osteoporosis treatment and screening in patients with rheumatoid arthritis compared to osteoarthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):713-723. Ruiz D, Oates JC, Kamen DL. Antiphospholipid antibodies and heart valve disease in systemic lupus erythematosus. Am J Med Sci. 2018 Mar;355(3):293-298. Sundararaj K, Rodgers JI, Marimuthu S, Siskind LJ, Bruner E, Nowling TK. Neuraminidase activity mediates IL-6 production by activated lupus-prone mesangial cells. Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F630-F642. Wang D, Zhang H, Liang J, Wang H, Hua B, Feng X, Gilkeson GS, Farge D, Shi S, Sun L. A long-term follow-up study of allogeneic mesenchymal stem/ stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Reports. 2018 Mar 13;10(3):933-941. Williams EM, Hyer JM, Viswanathan R, Faith TD, Voronca D, Gebregzaibher M, Oates JC, Egede L. Peer-to-peer mentoring for African American women with lupus: a feasibility pilot. Arthritis Care Res (Hoboken). 2018 Jun;70(6):908-917.
Zollars ES, Hyer M, Wolf B, Chapin R. Measuring lupus arthritis activity using contrasted high-field MRI. Associations with clinical measures of disease activity and novel patterns of disease. Lupus Sci Med. 2018 Jul 26;5(1). Pictured: Eric Zollars, M.D., Ph.D.
2018 ANNUAL REPORT
47
LEADERSHIP
Departmental Leadership Administration
Divisions
Don Rockey, M.D. Chair, Department of Medicine
Cardiology Thomas Di Salvo, M.D., MPH, MBA Division Director
Infectious Diseases Cassandra Salgado, M.D., MS Division Director
Steve Vinciguerra, MBA Division Administrator
Rebekah Shinta, MHA Division Administrator
Endocrinology Timothy Lyons, M.D., FRCP Division Director
Nephrology Joshua Lipschutz, M.D. Division Director
Elizabeth Swan Division Administrator
Sandra Hurley Division Administrator
Gastroenterology and Hepatology K. Mark Payne, M.D. Division Director (through December 2017)
Pulmonary and Critical Care Lynn Schnapp, M.D. Division Director
Georgia Brogdon, MBA, DHSc, FACHE, FACMPE Vice Chair, Finance and Administration Elisha Brownfield, M.D. Vice Chair, Leadership Development E. Benjamin Clyburn, M.D. Vice Chair, Graduate Medical Education Kimberly Davis, M.D. Vice Chair, Clinical Affairs Marc Heincelman, M.D. Vice Chair, Quality Improvement Brad Keith, M.D. Associate Vice Chair, Graduate Medical Education
Don Rockey, M.D. Interim Division Director Derek Sanford Division Administrator
Rheumatology and Immunology Jim Oates, M.D. Division Director
Samuel Schumann, M.D. Vice Chair, Quality Improvement
General Internal Medicine William Moran, M.D., MS Division Director
Richard Silver, M.D. Division Director (through August 2018)
Richard Silver, M.D. Vice Chair, Development
Brian Collins, MHA Division Administrator
Rebekah Shinta, MHA Division Administrator
Jim Oates, M.D. Vice Chair, Research
Hematology/Oncology Carolyn Britten, M.D. Division Director Lee Putney, MHA Division Administrator
48
Richard "Mac" Houck, MBA Division Administrator
D E PA R T M E N T O F M E D I C I N E
FA C U LT Y
Medicine Faculty Cardiology
Catalin Baicu, Ph.D. Richard Bayer, M.D. Amy Bradshaw, Ph.D. Michael Craig, M.D. Kristine DeLeon-Pennell, Ph.D. Federica del Monte, M.D., Ph.D. Thomas Di Salvo, M.D., MPH, MBA William Edwards, M.D. Valerian Fernandes, M.D. James Glenn, M.D. Michael Gold, M.D., Ph.D. David Gregg, IV, M.D. Kenneth Hanger, Jr., M.D. Brian Houston, M.D. Daniel Judge, M.D. Dhandapani Kuppuswamy, Ph.D. Robert Leman, M.D. Sheldon Litwin, M.D. Anbukarasi Maran, M.D. Paul McDermott, Ph.D. Donald Menick, Ph.D. Pamela Morris, M.D. Christopher Nielsen, M.D. Terrence O'Brien, M.D., MS Eric Powers, M.D. Bhavadharini Ramu, M.D. Robert Sisson, III, M.D., FACC Daniel Steinberg, M.D. J. Lacy Sturdivant, M.D. Marian Taylor, M.D. Ryan Tedford, M.D., FACC, FAHA Thomas Todoran, M.D., MSc Bruce Usher, M.D. Adrian Van Bakel, M.D., Ph.D. Stephen Vinciguerra, MBA John Wharton, M.D. Jeffrey Winterfield, M.D. Michael Zile, M.D. Peter Zwerner, M.D.
Endocrinology
Hesham El-Shewy, Ph.D. Jyotika Fernandes, M.D., M.B.B.S. Kathie Hermayer, M.D., MS Yan Huang, M.D., Ph.D. Ayad Jaffa, Ph.D.
Miran Jaffa, Ph.D. Alicia Jenkins, M.D. Harsha Karanchi, M.D. Richard Klein, Ph.D. Soonho Kwon, M.D., MS Katherine Lewis, M.D. Maria Lopes-Virella, M.D., Ph.D. Deirdre Luttrell, Ph.D. Louis Luttrell, M.D., Ph.D. Timothy Lyons, M.D., FRCP Nicoleta Sora, M.D. Jeremy Yu, M.D., Ph.D.
Gastroenterology and Hepatology Amit Agrawal, M.D. Andrew Brock, M.D. Donald Castell, M.D. Gregory Cote, M.D., MS Peter Cotton, M.D., FRCP, FRCS Pooja Elias, M.D., MPH B. Joseph Elmunzer, M.D., MSc Brenda Hoffman, M.D. Serhan Karvar, M.D. David Koch, M.D., MSCR Songling Liu, M.D. Bernadette Marriott, M.D. Jill Newman, MS Mark Payne, M.D. Don Rockey, M.D. Zengdun Shi, M.D. Heather Simpson, M.D. Adam Smolka, M.D. Wingkin Syn, Ph.D., MBBS Aylin Tansel, M.D. Ira Willner, M.D.
General Internal Medicine Jean-Christopher Arnaud, BS Neal Axon, M.D. Sarah Ball, Pharm.D. Jan Basile, M.D. Graham Beattie, M.D. John Bian, Ph.D. Kinfe Bishu, Ph.D. Stacy Blecher, M.D. Laurence Blumenthal, M.D. Jennifer Bracey, M.D.
Ashley Britell, M.D. Elisha Brownfield, M.D. Walter Brzezinski, M.D. Patrick Cawley, M.D., MBA Benjamin Clyburn, M.D. Patrick Coyne, MSN Theresa Cuoco, M.D. Kimberly Davis, M.D. Clara Dismuke, Ph.D. Ashley Duckett, M.D. Jennifer Dulin, M.D. John Gibson, M.D. Srivatsatejaswi Gundala, M.D. Michael Hawkins, M.D. Marc Heincelman, M.D. Elizabeth Higgins, M.D. Keri Holmes-Maybank, M.D. Leigh Jaimes, M.D. Benjamin Kalivas, M.D. Brad Keith, M.D. Elizabeth Kirkland, M.D. Rogers Kyle, III, M.D. Leslie Lenert, M.D. Leonard Lichtenstein, M.D. Cara Litvin, M.D. Cheryl Lynch, M.D., MPH Julianna Marwell, M.D. Patrick Mauldin, Ph.D. William Moran, M.D. Ernest Murray, M.D. Cheryl Neal, D.O. Mark Newbrough, M.D. Amanda Overstreet, D.O. Fletcher Penney, M.D. Pamela Pride, M.D. Bruce Sabin, M.D. Danielle Scheurer, M.D., MSCR Andrew Schreiner, M.D. Samuel Schumann, M.D. Russell Seymore, M.D. Sabra Slaughter, Ph.D. Avinash Srikanth, M.B.B.S. Zemin Su, MS James Thomas, M.D. Deanna Vroman, M.D. Leonidas Walthall, M.D. Phillip Warr, M.D.
2018 ANNUAL REPORT
49
FA C U LT Y
Medicine Faculty Phillip Warr, M.D. Kristin Wise, M.D. Jingwen Zhang, MS
Hematology/Oncology
Frank Brescia, M.D. Carolyn Britten, M.D. Robert Gemmill, Ph.D. Antonio Giordano, M.D., Ph.D. Sara Giordano, M.D. Theodore Gourdin, M.D. Charles Greenberg, M.D. Brian Hess, M.D. John Kaczmar, M.D. Michael Lilly, M.D. Amarendra Neppalli, M.D. Paul O'Brien, M.D. Daniel Reuben, M.D. Carol Sherman, M.D. Robert Stuart, M.D. Cynthia Timmers, Ph.D. John Wrangle, M.D., MPH
Infectious Diseases
Robert Cantey, M.D. Scott Curry, M.D. Susan Dorman, M.D. John Gnann, M.D. Heather Hughes, M.D. Evgenia Kagan, M.D. Stephanie Kirk, Pharm.D. Jessica Lewis, M.D. Camelia Marculescu, M.D., MSCR Eric Meissner, M.D., Ph.D. Amanda Parks, M.D. Cassandra Salgado, M.D., MS Maria Westerink, M.D.
Nephrology
Anand Achanti, M.D. Ehtesham Arif, Ph.D. Milos Budisavljevic, M.D. Ruth Campbell, M.D., MSPH Wayne Fitzgibbon, Ph.D. Tibor Fulop, M.D. Perry Halushka, M.D., Ph.D. Florence Hutchison, M.D.
50 50
D E PA R T M E N T O F M E D I C I N E
Daria Ilatovskaya, Ph.D. Seok-Hyung Kim, Ph.D. Zipporah Krishnasami, M.D. Darius Lazarus, M.D. Joshua Lipschutz, M.D. Glenn Lobo, Ph.D. Albert Maniscalco, M.D. Deepak Nihalani, Ph.D. Roberto Pisoni, M.D. David Ploth, M.D. Maria Aurora Posadas Salas, M.D. Vinaya Rao, M.D. Rachel Sturdivant, M.D. Michael Ullian, M.D. Xiaofeng Zuo, Ph.D.
Pulmonary and Critical Care Rahul Argula, M.D. Tatsiana Beiko, M.D., MSCR Alice Boylan, M.D. John Cox, M.D. Patrick Flume, M.D. Dee Ford, M.D., MSCR Michael Frye, M.D. Andrew Goodwin, M.D., MSCR Terrill Huggins, M.D. Ennis James, IV, M.D. Edward Kilb III, M.D. Chitra Lal, M.D. Robert Miller, M.D. Lawrence Mohr, M.D. Nandita Nadig, M.D., MSCR Luca Paoletti, M.D. Nicholas Pastis, Jr., M.D. Andrea Rinn, D.O. Richard Rissmiller, M.D. Lynn Schnapp, M.D. Gerard Silvestri, M.D., MS Charlton Strange, M.D. Nichole Tanner, M.D., MSCR Robert Vorona, M.D. Timothy Whelan, M.D. Carole Wilson, Ph.D.
Rheumatology and Immunology Alexander Awgulewitsch, Ph.D. Galina Bogatkevich, M.D., Ph.D.
Melissa Cunningham, M.D., Ph.D. Carol Feghali-Bostwick, Ph.D. Gary Gilkeson, M.D. Faye Hant, D.O., MSCR Stanley Hoffman, Ph.D. Diane Kamen, M.D., MSCR Rebecca Lee, M.D., Ph.D. Margaret Markiewicz, M.D. Tamara Nowling, Ph.D. Jim Oates, M.D. Paula Ramos, Ph.D. Katherine Silver, M.D. Richard Silver, M.D. Edwin Smith, M.D. Elena Tourkina, Ph.D. Betty Tsao, Ph.D. Celine Ward, M.D. Xian-Kui “John” Zhang, Ph.D. Eric Zollars, M.D., Ph.D.
2017 ANNUAL REPORT
51
Department of Medicine 96 Jonathan Lucas Street, Suite 803 MSC 623 Charleston, SC 29425-5500 medicine.musc.edu
THE MEDICAL UNIVERSITY OF SOUTH CAROLINA Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and 700 residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.4 billion. MUSC operates a 700-bed medical center, which includes a nationally recognized Children’s Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (one of 68 National Cancer Institute designated centers), Level I Trauma Center and Institute of Psychiatry.
Changing What’s Possible